Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Ophthalmology›Condition·Updated Jul 11, 2026·v1

Primary Open-Angle Glaucoma

Primary open-angle glaucoma is a chronic, progressive optic neuropathy and the leading cause of irreversible blindness worldwide, characterized by open anterior chamber angles, characteristic optic disc damage, and visual field loss, typically associated with elevated intraocular pressure (IOP), managed through IOP-lowering therapy with prostaglandin analogs, SLT, or surgery to prevent progression.

High Evidence480 references·10,450 words·42 min read·v1
ophthalmologyglaucomaprimary open-angle glaucomaoptic neuropathyintraocular pressureprostaglandin analogsselective laser trabeculoplastytrabeculectomyMIGS

Quick Reference

RxDrug of choiceProstaglandin F2α analog (e.g., latanoprost 0.005% once daily), most effective monotherapy class, mean IOP reduction -4.75 mmHg.
AltAlternativesBeta-blockers (timolol 0.5% BID), carbonic anhydrase inhibitors (dorzolamide 2% TID), alpha-2 agonists (brimonidine 0.2% BID), rho-kinase inhibitors (netarsudil 0.02% once daily), EP2 receptor agonists (omidenepag isopropyl 0.002% once daily).
⊘AvoidNon-selective beta-blockers in asthma/COPD/bradycardia; brimonidine in young children; two prostaglandin analogs simultaneously; non-dihydropyridine CCBs (diltiazem, verapamil) in heart failure.
DxTest of choiceOptical coherence tomography (OCT) of peripapillary RNFL and macular GCIPL for structural damage; standard automated perimetry (24-2 SITA) for functional visual field loss.
ScKey scoreHodapp-Parrish-Anderson (HPA) classification or modified Glaucoma Staging System (mGSS) for visual field severity staging. OHTS risk calculator for 5-year risk of POAG in ocular hypertensive patients.
→When to referAdvanced disease (severe visual field loss, IOP >30 mmHg despite maximal therapy, rapid progression), surgical candidacy, uncertain diagnosis, recurrent disc hemorrhages, or patient intolerance to medical therapy.
POAG is a silent, progressive optic neuropathy that requires lifelong IOP-lowering therapy to prevent blindness. Initiate with a prostaglandin analog or SLT; escalate to combination therapy, MIGS, or trabeculectomy based on disease severity and progression rate. Individualized target IOP (20-30% reduction from baseline) and vigilant monitoring are essential.
Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy characterized by characteristic structural damage to the optic nerve head and corresponding visual field loss, typically with an open anterior chamber angle. It is the leading cause of irreversible blindness worldwide, affecting over 57 million people, yet 50-90% of cases remain undiagnosed in the community because early disease is asymptomatic. Management centers on lowering intraocular pressure (IOP), the only modifiable risk factor, through medical therapy, selective laser trabeculoplasty, or incisional surgery, with individualized target IOPs based on disease severity and progression rate.

Overview and Recommendations

Background

  • •Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy defined by characteristic structural damage to the optic nerve head and corresponding visual field loss, typically with an open anterior chamber angle. It is the leading cause of irreversible blindness globally, affecting an estimated 57.5 million people in 2015, projected to rise to 65.5 million by 2020. Prevalence is highest in African-descent populations (OR 2.80 versus European ancestry) and increases with age (OR 1.32 per 5-year increase).
  • •The central pathophysiologic driver is increased resistance to aqueous humor outflow through the trabecular meshwork (TM), leading to elevated intraocular pressure (IOP). This resistance is driven by transforming growth factor beta-2 (TGF-β2)-mediated extracellular matrix remodeling, oxidative stress, and genetic susceptibility (e.g., MYOC mutations in ~5% of cases). Elevated IOP, along with vascular dysregulation and low cerebrospinal fluid pressure, mechanically and biochemically damages retinal ganglion cells (RGCs) at the lamina cribrosa, culminating in RGC apoptosis.
  • •POAG is subclassified into high-tension (IOP >21 mmHg at diagnosis) and normal-tension (NTG; IOP ≤21 mmHg) forms. NTG accounts for 30-50% of POAG in East Asian populations and is associated with vascular risk factors. Juvenile-onset open-angle glaucoma (JOAG) presents before age 40 years, often with IOPs of 30-50 mmHg and a strong family history; MYOC mutations account for 10-20% of cases.
  • •Key modifiable risk factors include higher systolic blood pressure (HR 1.16 per 10 mmHg increase), low body mass index (HR 1.30), and evening light exposure >1000 lux (HR 1.47). Protective factors include SGLT2 inhibitor use (HR 0.64), GLP-1 receptor agonist use (HR 0.58), nicotinamide supplementation (HR 0.34; NNT = 18), and omega-3 fatty acid supplementation (HR 0.45).
  • •The heritability of POAG is estimated at 0.30-0.50. A polygenic risk score (PRS) in the highest decile is associated with 7.4% prevalence versus 1.3% in the lowest decile (OR 1.74 per 1-SD increase). However, PRS performance varies by ancestry and is not yet ready for routine clinical use.

Evaluation

  • •Suspect POAG in any patient with asymptomatic visual field loss, difficulty with night vision, bumping into objects, or a family history of glaucoma. Remember that 50-90% of cases are undiagnosed because early disease is asymptomatic.
  • •Ask about age, race, family history of glaucoma, history of ocular trauma or surgery, systemic conditions (hypertension, diabetes, sleep apnea), and medication use (especially corticosteroids). Inquire about symptoms of angle closure (acute eye pain, headache, halos) to exclude acute angle-closure glaucoma.
  • •Examine visual acuity, pupillary reactions, and perform a thorough slit-lamp examination including anterior chamber depth, lens status, and signs of pseudoexfoliation or pigment dispersion. Measure intraocular pressure (IOP) with Goldmann applanation tonometry; note that a single reading is insufficient, consider diurnal variation and medication effects.
  • •Perform gonioscopy to confirm an open anterior chamber angle and exclude angle closure, pseudoexfoliation, or pigment dispersion. Direct gonioscopy (Goldmann or Zeiss lens) is essential for differentiating open-angle from angle-closure glaucoma.
  • •Examine the optic disc with a 78D or 90D lens for vertical cup-to-disc ratio (VCDR) >0.5, focal rim notching (especially inferotemporal and superotemporal), optic disc hemorrhages (splinter-shaped), and retinal nerve fiber layer (RNFL) defects. Asymmetry between eyes (VCDR difference ≥0.2) is suspicious.
  • •Measure central corneal thickness (CCT) with pachymetry; thinner CCT is a risk factor for POAG development and progression. In the Ocular Hypertension Treatment Study (OHTS), CCT was a significant predictor of conversion to POAG.
  • •Order optical coherence tomography (OCT) of the peripapillary RNFL and macular ganglion cell-inner plexiform layer (GCIPL) to quantify structural damage. Average and inferior RNFL parameters achieve diagnostic accuracy of 0.77. OCT angiography (OCTA) can assess peripapillary vessel density, which adds independent prognostic information (each 1% decrease in VD increases risk of VF progression by 5%).
  • •Perform standard automated perimetry (24-2 Swedish Interactive Thresholding Algorithm) to document functional visual field loss. The 10-2 test is more sensitive for central defects. Diagnostic criteria require a reproducible visual field defect compatible with glaucomatous optic neuropathy in the presence of an open angle.
  • •Diagnostic criteria for POAG include evidence of glaucomatous optic neuropathy (structural damage) and/or reproducible visual field loss (functional damage) with an open angle. IOP is a risk factor, not a criterion. The OHTS risk calculator integrates age, IOP, CCT, pattern standard deviation (PSD), and VCDR to estimate 5-year risk of POAG in ocular hypertensive patients.
  • •Consider genetic testing for MYOC, OPTN, and WDR36 mutations in early-onset or familial cases (e.g., JOAG), but routine genetic testing is not recommended for typical POAG due to low diagnostic yield (~8.9%).
  • •Differential diagnosis includes other causes of optic neuropathy and visual field loss: compressive lesions, ischemic optic neuropathy (NAION), autoimmune retinopathy, vitreomacular traction, and secondary glaucomas (pseudoexfoliative, pigmentary, uveitic). In normal-tension glaucoma, consider non-glaucomatous optic atrophy (e.g., compressive lesion, ischemic optic neuropathy).
  • •Red flags for urgent evaluation include rapid progression (visual field MD worsening ≥36%/year), recurrent disc hemorrhages, unilateral or highly asymmetric cupping, IOP >30 mmHg in a young patient, family history of blindness from glaucoma, and inferior hemifield defect encroaching within 5° of fixation.

Management

  • •Establish an individualized target IOP, typically a 20-30% reduction from untreated baseline, with lower targets (e.g., <15 mmHg) for advanced disease. The goal is to prevent progressive optic neuropathy and visual field loss.
  • •Initiate first-line medical therapy with a prostaglandin F2α analog (PGFA): latanoprost 0.005%, travoprost 0.004%, or bimatoprost 0.01%, one drop in the affected eye(s) once daily in the evening. PGFAs are the most effective monotherapy class, with a mean IOP reduction of -4.75 mmHg (high certainty).
  • •Alternative first-line options include the EP2 receptor agonist omidenepag isopropyl 0.002% once daily (noninferior to latanoprost) or selective laser trabeculoplasty (SLT). The LiGHT trial supports SLT as first-line due to similar efficacy, lower cost, and reduced medication burden.
  • •If target IOP is not achieved with monotherapy, add a second agent. The most effective dual combination is PGFA plus a carbonic anhydrase inhibitor (CAI) (e.g., brinzolamide 1% or dorzolamide 2% TID). Avoid using two prostaglandin analogs simultaneously, no additive effect, increased side effects. Avoid beta-blockers (timolol) in patients with asthma, COPD, or bradycardia.
  • •Consider fixed combinations to improve adherence, such as latanoprost/timolol, dorzolamide/timolol, or brinzolamide/brimonidine. Non-PGFA triple combinations (alpha-agonist + beta-blocker + CAI) achieve -7.22 mmHg IOP reduction.
  • •Offer selective laser trabeculoplasty (SLT) as a first-line or add-on therapy. SLT achieves a mean IOP reduction of 20-30% and can be repeated. If IOP reduction <20% at 3 months, consider repeat SLT or proceed to incisional surgery.
  • •When medical and laser therapy fail to achieve target IOP or disease progresses, proceed to incisional surgery. Trabeculectomy remains the gold standard, achieving a mean IOP of 10-12 mmHg in successful cases. However, it carries a higher risk of hypotony (51.1% at 2 years), bleb leaks, and infection.
  • •Minimally invasive glaucoma surgery (MIGS) is appropriate for mild-to-moderate POAG, especially when combined with cataract surgery. Options include trabecular microstents (iStent inject, Hydrus microstent), ab interno trabeculotomy (Kahook Dual Blade), and subconjunctival implants (Xen, MicroShunt). The Hydrus microstent combined with cataract surgery reduced the need for incisional glaucoma surgery (2.4% vs 6.2% at 5 years; NNT = 26).
  • •Glaucoma drainage devices (tube shunts) are used after failed trabeculectomy or in eyes with conjunctival scarring. The Ahmed valve and Baerveldt implant are common options.
  • •Monitor patients lifelong with regular IOP checks, OCT imaging, and visual field testing. The OHTS 20-year follow-up showed that even with treatment, the cumulative incidence of POAG was 41.9% in the medication group. Visual field progression occurs at a mean rate of -0.40 dB/year after diagnosis, with 21% of eyes progressing at ≥-1.0 dB/year.
  • •Escalate therapy if there is confirmed progression on perimetry or OCT, IOP consistently above target, or intolerance to medications. Consider switching from medical to laser or surgical therapy. The Fast-PACE study demonstrated that clustered testing over 6 months can identify fast progressors with 93% sensitivity.
  • •What NOT to do: Do not administer laser peripheral iridotomy in a patient with confirmed open angles, it is ineffective and may cause complications. Do not rely solely on a single medication in an acute setting; combination therapy is necessary. Do not use two prostaglandin analogs simultaneously. Avoid beta-blockers in patients with asthma or bradycardia. Avoid brimonidine in young children (risk of CNS depression).
  • •Refer to a glaucoma specialist when disease is advanced (severe visual field loss, IOP >30 mmHg despite maximal therapy, rapid progression), when surgical intervention is indicated, or when the diagnosis is uncertain (e.g., atypical optic disc appearance, normal-tension glaucoma with possible non-glaucomatous etiology).
  • •Discharge criteria for acute IOP elevation: IOP reduced to a safe level (<25 mmHg in severe disease), corneal edema resolved, no optic disc edema, and patient tolerating medications. Transition to long-term management with established IOP targets and follow-up interval.

Board Review — High Yield

  • •Silent thief of sight, POAG is asymptomatic until moderate-to-severe damage; 50-90% of cases are undiagnosed.
  • •Gold standard diagnostic combination, Optic disc cupping (VCDR >0.5) + RNFL thinning on OCT + reproducible visual field defect on perimetry.
  • •Prostaglandin analogs are first-line, Latanoprost 0.005% once daily reduces IOP by ~30% and has the longest treatment persistence.
  • •LiGHT trial, Selective laser trabeculoplasty (SLT) is noninferior to topical medication as first-line therapy and more cost-effective.
  • •Normal-tension glaucoma (NTG), IOP ≤21 mmHg; more common in Asian populations; consider vascular risk factors and OPTN/TBK1 mutations.
  • •Optic disc hemorrhage, Strong predictor of progression (OR 4.51); prompt intensified IOP-lowering and closer follow-up.
  • •Trabeculectomy vs MIGS, Trabeculectomy achieves lower mean IOP (10-12 mmHg) but with higher hypotony risk (51%); MIGS is safer for mild-moderate disease.
  • •Central corneal thickness (CCT), Thinner CCT is a risk factor for POAG development and progression; corrects IOP measurement.
  • •OCT angiography, Each 1% decrease in peripapillary vessel density increases risk of VF progression by 5%.
  • •Disc hemorrhage + peak RNFL thinning >4.5 µm/year, Two strongest actionable predictors of rapid progression; escalate therapy.

Deep Dive — Evidence Details

References

  1. [1]

    Mehta R, Ray RM, Tussing-Humphreys LM et al.. “Effect of Low-Fat Dietary Modification on Incident Open-Angle Glaucoma.” Ophthalmology (2022). PMID: 36410561 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, History and Evolution of Treatment
  2. [2]

    Lee PP, Levin LA, Walt JG et al.. “Cost of patients with primary open-angle glaucoma: a retrospective study of commercial insurance claims data.” Ophthalmology (2007). PMID: 17306876 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature
  3. [3]

    Clark RA, Wong RK. “Spherical Equivalent Refraction Versus Axial Length for Monitoring Childhood Myopia and Estimating Disease Risk: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2026). PMID: 41825844 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
  4. [4]

    Chan EW, Li X, Tham YC et al.. “Glaucoma in Asia: regional prevalence variations and future projections.” The British journal of ophthalmology (2015). PMID: 26112871 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management
  5. [5]

    Kapetanakis VV, Chan MP, Foster PJ et al.. “Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis.” The British journal of ophthalmology (2015). PMID: 26286821 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
  6. [6]

    Pan CW, Yang WY, Hu DN et al.. “Longitudinal Cohort Study on the Incidence of Primary Open-Angle Glaucoma in Bai Chinese.” American journal of ophthalmology (2017). PMID: 28104416 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Acute & Vision-Threatening Management
  7. [7]

    Rudnicka AR, Mt-Isa S, Owen CG et al.. “Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis.” Investigative ophthalmology & visual science (2006). PMID: 17003413 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
  8. [8]

    Liu W, Guo R, Wang S et al.. “Association Between Chronic Kidney Disease and Glaucoma: Results From the Lifelines Cohort Study and UK Biobank.” Investigative ophthalmology & visual science (2025). PMID: 41334958 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, History and Evolution of Treatment
  9. [9]

    Thapa SS, Paudyal I, Khanal S et al.. “A population-based survey of the prevalence and types of glaucoma in Nepal: the Bhaktapur Glaucoma Study.” Ophthalmology (2012). PMID: 22305097 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  10. [10]

    Ishida A, Miki T, Naito T et al.. “Surgical Results of Trabeculectomy among Groups Stratified by Prostaglandin-Associated Periorbitopathy Severity.” Ophthalmology (2022). PMID: 36522821 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management, History and Evolution of Treatment
  11. [11]

    Chauhan MZ, Elhusseiny AM, Kishor KS et al.. “Association of Primary Open-Angle Glaucoma with Diabetic Retinopathy among Patients with Type 1 and Type 2 Diabetes: A Large Global Database Study.” Ophthalmology (2024). PMID: 38215989 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Prevention, Screening & Surveillance
  12. [12]

    Dinn RB, Zimmerman MB, Shuba LM et al.. “Concordance of diurnal intraocular pressure between fellow eyes in primary open-angle glaucoma.” Ophthalmology (2007). PMID: 17467528 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  13. [13]

    Yao M, Kitayama K, Yu F et al.. “Association Between Myopia and Primary Open-Angle Glaucoma by Race and Ethnicity in Older Adults in the California Medicare Population.” JAMA ophthalmology (2023). PMID: 37103940 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Prevention, Screening & Surveillance
  14. [14]

    Han X, Souzeau E, Ong JS et al.. “Myocilin Gene Gln368Ter Variant Penetrance and Association With Glaucoma in Population-Based and Registry-Based Studies.” JAMA ophthalmology (2019). PMID: 30267046 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  15. [15]

    He W, Lee SS, Diaz Torres S et al.. “Predictive Power of Polygenic Risk Scores for Intraocular Pressure or Vertical Cup-Disc Ratio.” JAMA ophthalmology (2025). PMID: 39570582 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification
  16. [16]

    Kaplan RI, De Moraes CG, Cioffi GA et al.. “Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment.” JAMA ophthalmology (2015). PMID: 25741886 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Complications & Ocular Sequelae
  17. [17]

    Topouzis N, Kitayama K, Puran A et al.. “Association of Open-Angle Glaucoma With Dementia in California Medicare Beneficiaries.” American journal of ophthalmology (2024). PMID: 39029771 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  18. [18]

    Lerner SF, Singh K, Susanna R et al.. “RAND-like appropriateness methodology consensus for primary open-angle glaucoma in Latin America.” American journal of ophthalmology (2012). PMID: 22626620 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
  19. [19]

    Zhao AT, Di Rosa I, Salowe R et al.. “Predictors of Glaucoma Conversion in an African Ancestry Cohort: A Longitudinal Study.” American journal of ophthalmology (2025). PMID: 40782885 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Acute & Vision-Threatening Management, Prevention, Screening & Surveillance
  20. [20]

    Marshall H, Berry EC, Torres SD et al.. “Association Between Body Mass Index and Primary Open Angle Glaucoma in Three Cohorts.” American journal of ophthalmology (2022). PMID: 35970205 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Surgical, Laser & Procedural Considerations
  21. [21]

    Birla S, Gupta D, Somarajan BI et al.. “Classifying juvenile onset primary open angle glaucoma using cluster analysis.” The British journal of ophthalmology (2019). PMID: 31563868 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Prognosis & Natural History
  22. [22]

    Lim ZW, Chee ML, Thakur S et al.. “Albuminuria and Primary Open-Angle Glaucoma: the Singapore Chinese Eye Study (SCES).” The British journal of ophthalmology (2020). PMID: 32675061 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup, History and Evolution of Treatment
  23. [23]

    Guo B, Tan Y, Nygaard S et al.. “Prevalence of glaucoma in the Lao People's Democratic Republic: the Vientiane Eye Study.” The British journal of ophthalmology (2021). PMID: 33737304 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Acute & Vision-Threatening Management
  24. [24]

    Liu Y, Yao B, Chen X et al.. “Glaucoma in rural China (the Rural Epidemiology for Glaucoma in China (REG-China)): a national cross-sectional study.” The British journal of ophthalmology (2022). PMID: 35840290 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Acute & Vision-Threatening Management
  25. [25]

    Cho HK, Kee C. “Population-based glaucoma prevalence studies in Asians.” Survey of ophthalmology (2014). PMID: 24837853 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management
  26. [26]

    Liu W, Guo R, Song M et al.. “Associations Between Serum Uric Acid Levels and Glaucoma: Results From the LifeLines Cohort and UK Biobank.” Investigative ophthalmology & visual science (2026). PMID: 42370639 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism
  27. [27]

    Sakata K, Sakata LM, Sakata VM et al.. “Prevalence of glaucoma in a South brazilian population: Projeto Glaucoma.” Investigative ophthalmology & visual science (2007). PMID: 17962447 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Prevention, Screening & Surveillance
  28. [28]

    Lee JY, Jeong HJ, Lee JH et al.. “An investigation of lateral geniculate nucleus volume in patients with primary open-angle glaucoma using 7 tesla magnetic resonance imaging.” Investigative ophthalmology & visual science (2014). PMID: 24722700 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature
  29. [29]

    Nag A, Venturini C, Hysi PG et al.. “Copy number variation at chromosome 5q21.2 is associated with intraocular pressure.” Investigative ophthalmology & visual science (2013). PMID: 23599335 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  30. [30]

    Amiri I, Tang V, Mwanza JC et al.. “Glaucoma Diagnosis in Randomized Trials: Variability and the Need for Standardization.” Journal of glaucoma (2025). PMID: 41474870 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Ophthalmic Imaging and Functional Testing
  31. [31]

    Confalonieri F, Casarini B, Papapicco A et al.. “A Systematic Review of Micropulse Laser Trabeculoplasty (MLT) in Primary Open-Angle Glaucoma (POAG) Management: Efficacy, Safety, and Future Perspectives.” Biomedicines (2025). PMID: 39857796 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Prevention, Screening & Surveillance
  32. [32]

    Wu Z, Karunaratne S, Ang GS et al.. “Systematic review and appraisal of quality, definitions and treatment recommendations of clinical guidelines for glaucoma suspects.” Clinical & experimental ophthalmology (2023). PMID: 38093486 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature
  33. [33]

    Choudhari NS, Khanna RC, Marmamula S et al.. “Incidence of primary open angle glaucoma in the Andhra Pradesh Eye Disease Study (APEDS).” Eye (London, England) (2023). PMID: 37968514 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
  34. [34]

    Hewitt AW, Sanfilippo P, Ring MA et al.. “Mortality in primary open-angle glaucoma: 'two cupped discs and a funeral'.” Eye (London, England) (2009). PMID: 19247389 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  35. [35]

    Hoang TT, Van Bui A, Nguyen V et al.. “Comparison of perimetric Glaucoma Staging Systems in Asians with primary glaucoma.” Eye (London, England) (2020). PMID: 32518400 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  36. [36]

    Yan X, Zhang H, Li F et al.. “Surgical site characteristics after CLASS followed by ultrasound biomicroscopy and clinical grading scale: a 2-year follow-up.” Eye (London, England) (2020). PMID: 33139873 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism
  37. [37]

    Rickels KL, Chauhan MZ, Saeedi OJ et al.. “Diabetic Retinopathy as a Risk Factor for Ocular Hypertension or Primary Open Angle Glaucoma in a United States-Based Cohort Study.” Journal of glaucoma (2026). PMID: 41590998 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management, Prevention, Screening & Surveillance
  38. [38]

    Sit AJ, Gupta D, Kazemi A et al.. “Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.” American journal of ophthalmology (2021). PMID: 33524367 ↗

    L1RCTCited in: Pathophysiology & Mechanism, Complications & Ocular Sequelae
  39. [39]

    Ebneter A, Wagels B, Zinkernagel MS. “Non-invasive biometric assessment of ocular rigidity in glaucoma patients and controls.” Eye (London, England) (2008). PMID: 18309334 ↗

    L3TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism, Long-term & Definitive Management, Special Populations & Pregnancy
  40. [40]

    Nusinovici S, Li H, Thakur S et al.. “High-Density Lipoprotein 3 Cholesterol and Primary Open-Angle Glaucoma: Metabolomics and Mendelian Randomization Analyses.” Ophthalmology (2021). PMID: 34592243 ↗

    L2OTHERCited in: Pathophysiology & Mechanism
  41. [41]

    Souzeau E, Tram KH, Witney M et al.. “Myocilin Predictive Genetic Testing for Primary Open-Angle Glaucoma Leads to Early Identification of At-Risk Individuals.” Ophthalmology (2016). PMID: 27993484 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  42. [42]

    Pasquale LR, Willett WC, Rosner BA et al.. “Anthropometric measures and their relation to incident primary open-angle glaucoma.” Ophthalmology (2010). PMID: 20382429 ↗

    L2OTHERCited in: Pathophysiology & Mechanism
  43. [43]

    Berdahl JP, Allingham RR, Johnson DH. “Cerebrospinal fluid pressure is decreased in primary open-angle glaucoma.” Ophthalmology (2008). PMID: 18452762 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  44. [44]

    Nezu N, Usui Y, Saito A et al.. “Machine Learning Approach for Intraocular Disease Prediction Based on Aqueous Humor Immune Mediator Profiles.” Ophthalmology (2021). PMID: 33484732 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  45. [45]

    Ussa F, Fernandez I, Brion M et al.. “Association between SNPs of Metalloproteinases and Prostaglandin F2α Receptor Genes and Latanoprost Response in Open-Angle Glaucoma.” Ophthalmology (2015). PMID: 25704319 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  46. [46]

    Loomis SJ, Kang JH, Weinreb RN et al.. “Association of CAV1/CAV2 genomic variants with primary open-angle glaucoma overall and by gender and pattern of visual field loss.” Ophthalmology (2013). PMID: 24572674 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  47. [47]

    Mabuchi F, Sakurada Y, Kashiwagi K et al.. “Association between genetic variants associated with vertical cup-to-disc ratio and phenotypic features of primary open-angle glaucoma.” Ophthalmology (2012). PMID: 22584021 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  48. [48]

    Gospe SM, Bhatti MT, Chavis PS. “Tug of war.” Survey of ophthalmology (2014). PMID: 25891028 ↗

    L4CASE_REPORTCited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
  49. [49]

    Baudouin C, Kolko M, Melik-Parsadaniantz S et al.. “Inflammation in Glaucoma: From the back to the front of the eye, and beyond.” Progress in retinal and eye research (2020). PMID: 33075485 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
  50. [50]

    Saccuzzo EG, Youngblood HA, Lieberman RL. “Myocilin misfolding and glaucoma: A 20-year update.” Progress in retinal and eye research (2023). PMID: 37217093 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  51. [51]

    Gu X, Reagan AM, McClellan ME et al.. “Caveolins and caveolae in ocular physiology and pathophysiology.” Progress in retinal and eye research (2016). PMID: 27664379 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  52. [52]

    Danford ID, Verkuil LD, Choi DJ et al.. “Characterizing the "POAGome": A bioinformatics-driven approach to primary open-angle glaucoma.” Progress in retinal and eye research (2017). PMID: 28223208 ↗

    L2REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
  53. [53]

    Enyong EN, Gurley JM, De Ieso ML et al.. “Caveolar and non-Caveolar Caveolin-1 in ocular homeostasis and disease.” Progress in retinal and eye research (2022). PMID: 35729002 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  54. [54]

    Reina-Torres E, De Ieso ML, Pasquale LR et al.. “The vital role for nitric oxide in intraocular pressure homeostasis.” Progress in retinal and eye research (2020). PMID: 33253900 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  55. [55]

    Janssen SF, Gorgels TG, Ramdas WD et al.. “The vast complexity of primary open angle glaucoma: disease genes, risks, molecular mechanisms and pathobiology.” Progress in retinal and eye research (2013). PMID: 24055863 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup
  56. [56]

    Wang Z, Wiggs JL, Aung T et al.. “The genetic basis for adult onset glaucoma: Recent advances and future directions.” Progress in retinal and eye research (2022). PMID: 35589495 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  57. [57]

    Michelessi M, Bicket AK, Lindsley K. “Cyclodestructive procedures for non-refractory glaucoma.” The Cochrane database of systematic reviews (2018). PMID: 29694684 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Special Populations & Pregnancy
  58. [58]

    King AJ, Shah A, Nikita E et al.. “Subconjunctival draining minimally-invasive glaucoma devices for medically uncontrolled glaucoma.” The Cochrane database of systematic reviews (2018). PMID: 30554418 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  59. [59]

    Clement Freiberg J, von Spreckelsen A, Kolko M et al.. “Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.” The Cochrane database of systematic reviews (2022). PMID: 35686679 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Special Populations & Pregnancy
  60. [60]

    Chiquet C, Claustrat B, Thuret G et al.. “Melatonin concentrations in aqueous humor of glaucoma patients.” American journal of ophthalmology (2006). PMID: 16876520 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  61. [61]

    Mathew R, Barton K. “Anti--vascular endothelial growth factor therapy in glaucoma filtration surgery.” American journal of ophthalmology (2011). PMID: 21620367 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  62. [62]

    Siegfried CJ, Shui YB. “Intraocular Oxygen and Antioxidant Status: New Insights on the Effect of Vitrectomy and Glaucoma Pathogenesis.” American journal of ophthalmology (2019). PMID: 30772349 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  63. [63]

    Topouzis F, Wilson MR, Harris A et al.. “Risk factors for primary open-angle glaucoma and pseudoexfoliative glaucoma in the Thessaloniki eye study.” American journal of ophthalmology (2011). PMID: 21664597 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  64. [64]

    Topouzis F, Wilson MR, Harris A et al.. “Association of open-angle glaucoma with perfusion pressure status in the Thessaloniki Eye Study.” American journal of ophthalmology (2013). PMID: 23394905 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  65. [65]

    Suh MH, Weinreb RN, Walker E et al.. “Optic Disc Microvasculature Reduction and Visual Field Progression in Primary Open-Angle Glaucoma.” American journal of ophthalmology (2025). PMID: 39921101 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  66. [66]

    Gong B, Qu C, Li X et al.. “Mutation spectrum of CYP1B1 in Chinese patients with primary open-angle glaucoma.” The British journal of ophthalmology (2014). PMID: 25527694 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  67. [67]

    Jasty U, Harris A, Siesky B et al.. “Optic disc haemorrhage and primary open-angle glaucoma: a clinical review.” The British journal of ophthalmology (2020). PMID: 32071036 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification
  68. [68]

    Chen SY, Ling A, Chan PP et al.. “Association of polymorphisms in 17 loci with primary open-angle glaucoma in Chinese and Japanese.” The British journal of ophthalmology (2026). PMID: 41338940 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  69. [69]

    Alaghband P, Beltran-Agulló L, Galvis EA et al.. “Effect of phacoemulsification on facility of outflow.” The British journal of ophthalmology (2018). PMID: 29654113 ↗

    L4OTHERCited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup, Surgical, Laser & Procedural Considerations
  70. [70]

    Huynh B, Shah P, Sii F et al.. “Low systemic vitamin D as a potential risk factor in primary open-angle glaucoma: a review of current evidence.” The British journal of ophthalmology (2020). PMID: 32606080 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Surgical, Laser & Procedural Considerations
  71. [71]

    Keenan TD, Goldacre R, Goldacre MJ. “Associations between primary open angle glaucoma, Alzheimer's disease and vascular dementia: record linkage study.” The British journal of ophthalmology (2014). PMID: 25370081 ↗

    L2OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  72. [72]

    Andrews R, Ressiniotis T, Turnbull DM et al.. “The role of mitochondrial haplogroups in primary open angle glaucoma.” The British journal of ophthalmology (2006). PMID: 16547333 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  73. [73]

    Andrew NH, Akkach S, Casson RJ. “A review of aqueous outflow resistance and its relevance to microinvasive glaucoma surgery.” Survey of ophthalmology (2019). PMID: 31425701 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
  74. [74]

    Tamm ER, Fuchshofer R. “What increases outflow resistance in primary open-angle glaucoma?” Survey of ophthalmology (2007). PMID: 17998032 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  75. [75]

    Sanfilippo PG, Hewitt AW, Hammond CJ et al.. “The heritability of ocular traits.” Survey of ophthalmology (2010). PMID: 20851442 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
  76. [76]

    Pache M, Flammer J. “A sick eye in a sick body? Systemic findings in patients with primary open-angle glaucoma.” Survey of ophthalmology (2006). PMID: 16644363 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
  77. [77]

    Skeie JM, Nishimura DY, Wang CL et al.. “Mitophagy: An Emerging Target in Ocular Pathology.” Investigative ophthalmology & visual science (2021). PMID: 33724294 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  78. [78]

    Monu M, Kumar B, Asfiya R et al.. “Metabolomic Profiling of Aqueous Humor From Glaucoma Patients Identifies Metabolites With Anti-Inflammatory and Neuroprotective Potential in Mice.” Investigative ophthalmology & visual science (2025). PMID: 40402521 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management, Special Populations & Pregnancy
  79. [79]

    Huang OS, Seet LF, Ho HW et al.. “Altered Iris Aquaporin Expression and Aqueous Humor Osmolality in Glaucoma.” Investigative ophthalmology & visual science (2021). PMID: 33616622 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Acute & Vision-Threatening Management
  80. [80]

    Najjar RP, Sharma S, Drouet M et al.. “Disrupted Eye Movements in Preperimetric Primary Open-Angle Glaucoma.” Investigative ophthalmology & visual science (2017). PMID: 28448671 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Clinical Presentation
  81. [81]

    Liu Y, Siegfried CJ, Wu H et al.. “Tissue-Specific Antioxidant Capacity in Primary Open-Angle Glaucoma Patients.” Investigative ophthalmology & visual science (2026). PMID: 41891762 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
  82. [82]

    Johns KL, Faralli JA, Filla MS et al.. “Age-Related Dysregulation of α5β1 and αvβ3 Integrin Activity Alters Contractile Properties of Trabecular Meshwork Cells.” Investigative ophthalmology & visual science (2025). PMID: 40488712 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup
  83. [83]

    Park DY, Kim M, Cha SC. “Cytokine and Growth Factor Analysis in Exfoliation Syndrome and Glaucoma.” Investigative ophthalmology & visual science (2021). PMID: 34870675 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  84. [84]

    Kim HR, Weinreb RN, Zangwill LM et al.. “Characteristics of Focal Gamma Zone Parapapillary Atrophy.” Investigative ophthalmology & visual science (2020). PMID: 32176268 ↗

    L4OTHERCited in: Pathophysiology & Mechanism, Ophthalmic Imaging and Functional Testing
  85. [85]

    Morino K, Meguro A, Nagasaki M et al.. “Genome-Wide Meta-Analysis for High Myopia Provides Insights into Disease Mechanisms and Reveals a Causal Link to Primary Open-Angle Glaucoma.” Ophthalmology science (2026). PMID: 42064014 ↗

    L3SR_OBSCited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup
  86. [86]

    Fingert JH. “Primary open-angle glaucoma genes.” Eye (London, England) (2011). PMID: 21562585 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
  87. [87]

    Mossböck G, Weger M, Moray M et al.. “TNF-alpha promoter polymorphisms and primary open-angle glaucoma.” Eye (London, England) (2005). PMID: 16138112 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  88. [88]

    Choquet H, Wiggs JL, Khawaja AP. “Clinical implications of recent advances in primary open-angle glaucoma genetics.” Eye (London, England) (2019). PMID: 31645673 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Complications & Ocular Sequelae
  89. [89]

    Pasquale LR, Kang JH. “Female reproductive factors and primary open-angle glaucoma in the Nurses' Health Study.” Eye (London, England) (2011). PMID: 21336255 ↗

    L2OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, History and Evolution of Treatment, Special Populations & Pregnancy
  90. [90]

    Gemenetzi M, Yang Y, Lotery AJ. “Current concepts on primary open-angle glaucoma genetics: a contribution to disease pathophysiology and future treatment.” Eye (London, England) (2011). PMID: 22173078 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup, Prevention, Screening & Surveillance
  91. [91]

    Zhai R, Cheng J, Xu H et al.. “Mean amplitude of intraocular pressure excursions: a new assessment parameter for 24-h pressure fluctuations in glaucoma patients.” Eye (London, England) (2020). PMID: 32973338 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  92. [92]

    Le YTT, Chuang SH, Tran DNA et al.. “The correlation between C-reactive protein and normal tension glaucoma disease: A meta-analysis.” European journal of ophthalmology (2025). PMID: 41411088 ↗

    L3SR_OBSCited in: Pathophysiology & Mechanism
  93. [93]

    Yu P, Hu B, He Y et al.. “Quantitative gonioscopic assessment of anterior chamber angle remodeling using the spaeth classification after Schlemm's canal-based MIGS (3T) in POAG: a one-year retrospective study.” BMC ophthalmology (2026). PMID: 42050494 ↗

    L4COHORTCited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup, Surgical, Laser & Procedural Considerations
  94. [94]

    Samanchi R, Kaur S, Dada T et al.. “Neurophysiological Evidence of Visual Cortical Alterations in Mild Primary Glaucoma: A Resting-State EEG Microstate Study.” Brain topography (2026). PMID: 42410283 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup
  95. [95]

    Verticchio Vercellin A, Wood K, Pasquale LR et al.. “The Future of Glaucoma: Data, AI, and Precision Medicine for Patient-Centered Care.” Journal of glaucoma (2026). PMID: 42384719 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  96. [96]

    Beri N, Patil A, Sharma A et al.. “Comparative Evaluation of Functional Aqueous Humor Outflow in Primary Open Angle Glaucoma versus Primary Angle Closure Glaucoma using Aqueous Angiography.” Journal of glaucoma (2026). PMID: 42340241 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  97. [97]

    Fan X, Bilir EK, Kingston OA et al.. “Transforming Growth Factor beta-2 (TGFβ2) Drives Trabecular Meshwork Progenitor Cell Differentiation Through SMAD2/3 Signalling.” Stem cells (Dayton, Ohio) (2026). PMID: 42191673 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  98. [98]

    Baker ND, Barnebey HS, Moster MR et al.. “Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: One-Year Results from a 2-Year Randomized, Multicenter Study.” Ophthalmology (2021). PMID: 34051211 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
  99. [99]

    Liu JC, Jammal AA, Scherer R et al.. “Predicting Retinal Nerve Fiber Layer Thickness From Ocular Hypertension Treatment Study Optic Disc Photographs.” JAMA ophthalmology (2025). PMID: 40569586 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Special Populations & Pregnancy
  100. [100]

    Jampel HD, Chon BH, Stamper R et al.. “Effectiveness of intraocular pressure-lowering medication determined by washout.” JAMA ophthalmology (2014). PMID: 24481483 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Special Populations & Pregnancy
  101. [101]

    Tham YC, Li X, Wong TY et al.. “Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.” Ophthalmology (2014). PMID: 24974815 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Prevention, Screening & Surveillance
  102. [102]

    Stuart KV, de Vries VA, Schuster AK et al.. “Prevalence of Glaucoma in Europe and Projections to 2050: Findings from the European Eye Epidemiology Consortium.” Ophthalmology (2025). PMID: 40499787 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  103. [103]

    Zhao J, Solano MM, Oldenburg CE et al.. “Prevalence of Normal-Tension Glaucoma in the Chinese Population: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2018). PMID: 30352196 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  104. [104]

    Li X, Sun W, Xiao X et al.. “Biallelic variants in CPAMD8 are associated with primary open-angle glaucoma and primary angle-closure glaucoma.” The British journal of ophthalmology (2021). PMID: 34154991 ↗

    L3SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management
  105. [105]

    Kolli A, Sekimitsu S, Wang J et al.. “Background polygenic risk modulates the association between glaucoma and cardiopulmonary diseases and measures: an analysis from the UK Biobank.” The British journal of ophthalmology (2022). PMID: 35361574 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  106. [106]

    Chen J, Ling Y, Zhu Y et al.. “Early Life Body Size Trajectory and the Risk of Primary Open-angle Glaucoma: A Retrospective Cohort Study.” American journal of ophthalmology (2025). PMID: 40780580 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup
  107. [107]

    Pan SY, Weng CH, Tsai SF et al.. “Comparative Risk of Glaucoma in Patients Using Sodium-glucose Cotransporter-2 Inhibitors and Metformin: A Multinational Cohort Study.” American journal of ophthalmology (2025). PMID: 40976317 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy
  108. [108]

    Chen M, Yu X, Xu J et al.. “Association of Gene Polymorphisms With Primary Open Angle Glaucoma: A Systematic Review and Meta-Analysis.” Investigative ophthalmology & visual science (2019). PMID: 30901387 ↗

    L3SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  109. [109]

    George R, Panda S, Vijaya L. “Blindness in glaucoma: primary open-angle glaucoma versus primary angle-closure glaucoma-a meta-analysis.” Eye (London, England) (2021). PMID: 34645961 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management
  110. [110]

    Wong NSQ, Jin E, Goh CXY et al.. “The effect of selective laser trabeculoplasty on the intraocular pressure of the contralateral eye - a systematic review and meta-analysis.” Eye (London, England) (2026). PMID: 41547974 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  111. [111]

    Allan KC, Joo JH, Kim S et al.. “Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration.” Ophthalmology (2025). PMID: 39863057 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations
  112. [112]

    Vasu P, Dorairaj EA, Weinreb RN et al.. “Risk of Glaucoma in Patients without Diabetes Using a Glucagon-Like Peptide 1 Receptor Agonist.” Ophthalmology (2025). PMID: 39978437 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations
  113. [113]

    Akiyama M, Tamiya G, Fujiwara K et al.. “Genetic Risk Stratification of Primary Open-Angle Glaucoma in Japanese Individuals.” Ophthalmology (2024). PMID: 39023470 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification
  114. [114]

    Sekimitsu S, Selvan K, Zhao Y et al.. “Genetic Risk for Open-Angle Glaucoma Subtypes Is Associated with Specific Visual Field Defect Classes.” Ophthalmology (2025). PMID: 40222549 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup
  115. [115]

    Sekimitsu S, Ghazal N, Aziz K et al.. “Primary Open-Angle Glaucoma Polygenic Risk Score and Risk of Disease Onset: A Post Hoc Analysis of a Randomized Clinical Trial.” JAMA ophthalmology (2024). PMID: 39509108 ↗

    L1OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Prognosis & Natural History
  116. [116]

    Gordon MO, Gao F, Burkland J et al.. “Diagnosis of Primary Open-Angle Glaucoma and Mental Health Status.” JAMA ophthalmology (2025). PMID: 40471560 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup
  117. [117]

    Chang-Wolf JM, Kinzy TG, Driessen SJ et al.. “Performance of Polygenic Risk Scores for Primary Open-Angle Glaucoma in Populations of African Descent.” JAMA ophthalmology (2025). PMID: 39541127 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
  118. [118]

    Sekimitsu S, Xiang D, Smith SL et al.. “Deep Ocular Phenotyping Across Primary Open-Angle Glaucoma Genetic Burden.” JAMA ophthalmology (2023). PMID: 37589995 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Prevention, Screening & Surveillance
  119. [119]

    Liu YL, Tsai JY, Chiu KY et al.. “Ocular Risks of Topical Atropine Prescriptions Among Taiwanese Children.” JAMA ophthalmology (2025). PMID: 40932733 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Special Populations & Pregnancy
  120. [120]

    Muayad J, Sallam AB, De Francesco T et al.. “Nicotinamide Supplementation and Primary Open-Angle Glaucoma in Patients With Ocular Hypertension.” JAMA ophthalmology (2026). PMID: 42424069 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations
  121. [121]

    Piyasena MP, Daka Q, Qureshi R et al.. “Prognostic factors associated with progression of open-angle glaucoma in adults.” The Cochrane database of systematic reviews (2025). PMID: 41370133 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Prevention, Screening & Surveillance
  122. [122]

    Abboud I, Fam A, Almobayed A et al.. “Association Between Pseudoexfoliation Glaucoma and Central Serous Chorioretinopathy.” American journal of ophthalmology (2026). PMID: 41819515 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment
  123. [123]

    Chen J, Xiao Y, Chen X et al.. “Association Between Body Composition and Risk of Primary Open-Angle Glaucoma.” American journal of ophthalmology (2025). PMID: 41422857 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup
  124. [124]

    Tseng VL, Kitayama K, Yu F et al.. “Prevalence and Severity of Glaucoma in the California Medicare Population.” American journal of ophthalmology (2023). PMID: 37898281 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Prevention, Screening & Surveillance
  125. [125]

    Chen J, Huang S, Zhuo X et al.. “Association Between Outdoor Daylight Exposure Duration and Primary Open-Angle Glaucoma.” American journal of ophthalmology (2025). PMID: 40975158 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  126. [126]

    Mahmoudinezhad G, Salazar D, Morales E et al.. “Risk factors for microcystic macular oedema in glaucoma.” The British journal of ophthalmology (2021). PMID: 34740886 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Complications & Ocular Sequelae
  127. [127]

    Wostyn P, Audenaert K, De Deyn PP. “Alzheimer's disease and glaucoma: is there a causal relationship?” The British journal of ophthalmology (2009). PMID: 19286688 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  128. [128]

    Chan MPY, Khawaja AP, Broadway DC et al.. “Risk factors for previously undiagnosed primary open-angle glaucoma: the EPIC-Norfolk Eye Study.” The British journal of ophthalmology (2021). PMID: 34172506 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Prevention, Screening & Surveillance
  129. [129]

    Knecht KT, Chiriac G, Guan HD. “The potential impact of a vegetarian diet on glaucoma.” Survey of ophthalmology (2024). PMID: 38768761 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management
  130. [130]

    Liu W, Guo R, Huang D et al.. “Co-occurrence of chronic kidney disease and glaucoma: Epidemiology and etiological mechanisms.” Survey of ophthalmology (2022). PMID: 36088997 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management
  131. [131]

    Kouassi Nzoughet J, Chao de la Barca JM, Guehlouz K et al.. “Nicotinamide Deficiency in Primary Open-Angle Glaucoma.” Investigative ophthalmology & visual science (2019). PMID: 31185090 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors
  132. [132]

    Pan SY, Weng CH, Tien PT et al.. “Association Between Statin Use and Glaucoma Risk: A Population-Based Study.” Investigative ophthalmology & visual science (2025). PMID: 41328992 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy
  133. [133]

    Macri C, Wong CX, Tu SJ et al.. “Blood Pressure Measures and Incident Primary Open-Angle Glaucoma.” Investigative ophthalmology & visual science (2022). PMID: 36469027 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup
  134. [134]

    Pradhan ZS, Rao HL, Dixit S et al.. “Choroidal Microvascular Dropout in Pseudoexfoliation Glaucoma.” Investigative ophthalmology & visual science (2019). PMID: 31108546 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification
  135. [135]

    Gupta P, Thakur S, Wong CMJ et al.. “Glaucoma in Older Asians Aged 60 to 100 Years: Prevalence, Factors, Trends, and Projections (2024-2040).” Investigative ophthalmology & visual science (2025). PMID: 40704860 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Special Populations & Pregnancy, Prevention, Screening & Surveillance
  136. [136]

    Starr MR, Huang D, Wong JC et al.. “PREVALENCE, CHARACTERISTICS, AND OUTCOMES OF RHEGMATOGENOUS RETINAL DETACHMENT IN EYES WITH TRABECULECTOMY OR GLAUCOMA DRAINAGE DEVICES.” Retina (Philadelphia, Pa.) (2022). PMID: 35963003 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  137. [137]

    Hayreh SS, Zimmerman MB. “Ocular neovascularization associated with central and hemicentral retinal vein occlusion.” Retina (Philadelphia, Pa.) (2012). PMID: 22495331 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Clinical Examination and Diagnostic Workup
  138. [138]

    Xue CC, Li H, Chee ML et al.. “Protective Role of Metformin in Glaucoma: Prospective Cohort Study, Meta-Analysis, and Drug-Target Mendelian Randomization.” Ophthalmology science (2026). PMID: 41816092 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  139. [139]

    Hamid S, Desai P, Hysi P et al.. “Population screening for glaucoma in UK: current recommendations and future directions.” Eye (London, England) (2021). PMID: 34345031 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prevention, Screening & Surveillance
  140. [140]

    Kerr N, Ratnarajan G, Wang J et al.. “Multicentre study comparing ab-interno canaloplasty and trabecular micro-bypass stent in primary open-angle glaucoma.” Eye (London, England) (2026). PMID: 42049871 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  141. [141]

    Pan SY, Weng CH, Sheen YJ et al.. “Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study.” Ophthalmology science (2026). PMID: 42383218 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup
  142. [142]

    Wu X, Zhang X, Jiang Y et al.. “Association of high-intensity evening light exposure with risk of incident age-related macular degeneration, cataract, and glaucoma: a prospective cohort study of 82,826 participants.” GeroScience (2026). PMID: 42230852 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  143. [143]

    Zhou MY, Reed H, Singh RP et al.. “Association Between Systemic Comorbidity Burden and Glaucoma Progression: A 5-Year Cohort Study.” Journal of glaucoma (2026). PMID: 42224658 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  144. [144]

    Pan SY, Sheen YJ, Weng CH et al.. “Relationship Between Omega-3 Fatty Acids and Glaucoma Risk in Patients With Dry Eye Disease: A Multinational Retrospective Cohort Study.” Translational vision science & technology (2026). PMID: 42223316 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management
  145. [145]

    Chen DF, Wang T, Zhang J et al.. “Relationship between long-term blood pressure fluctuations and visual field progression in primary open-angle glaucoma: a prospective cohort study.” Eye and vision (London, England) (2026). PMID: 42169070 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Prognosis & Natural History
  146. [146]

    Martínez-de-la-Casa JM, Marcos-Parra MT, Millá-Griñó E et al.. “Three-Year Outcomes and Safety of the XEN63 Gel Stent: A Multicenter Prospective Study in Primary Open-Angle Glaucoma.” Journal of clinical medicine (2026). PMID: 42123261 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
  147. [147]

    Ou Y, Goldberg I, Migdal C et al.. “A critical appraisal and comparison of the quality and recommendations of glaucoma clinical practice guidelines.” Ophthalmology (2011). PMID: 21507487 ↗

    L5GUIDELINECited in: Clinical Presentation, Acute & Vision-Threatening Management
  148. [148]

    Ahmed IIK, De Francesco T, Rhee D et al.. “Long-term Outcomes from the HORIZON Randomized Trial for a Schlemm's Canal Microstent in Combination Cataract and Glaucoma Surgery.” Ophthalmology (2022). PMID: 35218867 ↗

    L1RCTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History
  149. [149]

    Vold S, Ahmed II, Craven ER et al.. “Two-Year COMPASS Trial Results: Supraciliary Microstenting with Phacoemulsification in Patients with Open-Angle Glaucoma and Cataracts.” Ophthalmology (2016). PMID: 27506486 ↗

    L1RCTCited in: Clinical Presentation, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History
  150. [150]

    Law SK, Lowe S, Law SM et al.. “Prospective Evaluation of Acupuncture as Treatment for Glaucoma.” American journal of ophthalmology (2015). PMID: 25935101 ↗

    L1RCTCited in: Clinical Presentation, Long-term & Definitive Management, Complications & Ocular Sequelae, Prognosis & Natural History
  151. [151]

    Yang Y, Jiang Y, Huang S et al.. “Laser in Glaucoma and Ocular Hypertension Trial (LIGHT) in China - A Randomized Controlled Trial: Design and Baseline Characteristics.” American journal of ophthalmology (2021). PMID: 33951448 ↗

    L1RCTCited in: Clinical Presentation, Special Populations & Pregnancy
  152. [152]

    Reiss G, Clifford B, Vold S et al.. “Safety and Effectiveness of CyPass Supraciliary Micro-Stent in Primary Open-Angle Glaucoma: 5-Year Results from the COMPASS XT Study.” American journal of ophthalmology (2019). PMID: 31377287 ↗

    L2RCTCited in: Clinical Presentation, Acute & Vision-Threatening Management, Complications & Ocular Sequelae, Prognosis & Natural History
  153. [153]

    Gazzard G, Konstantakopoulou E, Garway-Heath D et al.. “Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre, randomised controlled trial: design and methodology.” The British journal of ophthalmology (2017). PMID: 28903966 ↗

    L1RCTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Special Populations & Pregnancy
  154. [154]

    Wong MOM, Lai IS, Chan PP et al.. “Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial.” The British journal of ophthalmology (2020). PMID: 32606078 ↗

    L1RCTCited in: Clinical Presentation, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations
  155. [155]

    Konstantakopoulou E, Gazzard G, Vickerstaff V et al.. “The Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre randomised controlled trial: baseline patient characteristics.” The British journal of ophthalmology (2017). PMID: 28982956 ↗

    L1RCTCited in: Clinical Presentation, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Special Populations & Pregnancy
  156. [156]

    Siesky B, Harris A, Cantor LB et al.. “A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma.” The British journal of ophthalmology (2008). PMID: 18369067 ↗

    L1RCTCited in: Clinical Presentation, Complications & Ocular Sequelae
  157. [157]

    Rouland JF, Traverso CE, Stalmans I et al.. “Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.” The British journal of ophthalmology (2012). PMID: 23203707 ↗

    L1RCTCited in: Clinical Presentation, Complications & Ocular Sequelae
  158. [158]

    Gagliano C, Ortisi E, Pulvirenti L et al.. “Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial.” Investigative ophthalmology & visual science (2011). PMID: 21705689 ↗

    L1RCTCited in: Clinical Presentation, Complications & Ocular Sequelae
  159. [159]

    Choritz L, Mansouri K, van den Bosch J et al.. “Telemetric Measurement of Intraocular Pressure via an Implantable Pressure Sensor-12-Month Results from the ARGOS-02 Trial.” American journal of ophthalmology (2019). PMID: 31545953 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation, Prognosis & Natural History
  160. [160]

    Anand A, Negi S, Khokhar S et al.. “Role of early trabeculectomy in primary open-angle glaucoma in the developing world.” Eye (London, England) (2005). PMID: 16200053 ↗

    L1RCTCited in: Clinical Presentation, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
  161. [161]

    Gilmour DF, Manners TD, Devonport H et al.. “Viscocanalostomy versus trabeculectomy for primary open angle glaucoma: 4-year prospective randomized clinical trial.” Eye (London, England) (2007). PMID: 17293790 ↗

    L1RCTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, History and Evolution of Treatment
  162. [162]

    Arnalich-Montiel F, Muñoz-Negrete FJ, Rebolleda G et al.. “Cup-to-disc ratio: agreement between slit-lamp indirect ophthalmoscopic estimation and stratus optical coherence tomography measurement.” Eye (London, England) (2006). PMID: 16680099 ↗

    L4RCTCited in: Clinical Presentation, Ophthalmic Imaging and Functional Testing
  163. [163]

    Prata TS, Piassi MV, Melo LA. “Changes in visual function after intraocular pressure reduction using antiglaucoma medications.” Eye (London, England) (2008). PMID: 18670465 ↗

    L1RCTCited in: Clinical Presentation, Special Populations & Pregnancy
  164. [164]

    Iwao K, Inatani M, Tanihara H. “Success rates of trabeculotomy for steroid-induced glaucoma: a comparative, multicenter, retrospective cohort study.” American journal of ophthalmology (2011). PMID: 21396622 ↗

    L2COHORTCited in: Clinical Presentation
  165. [165]

    Dhalla K, Cousens S, Murdoch IE. “Phacoemulsification compared with phacotrabeculectomy surgery: a within-person observational cohort study.” The British journal of ophthalmology (2017). PMID: 28416493 ↗

    L2COHORTCited in: Clinical Presentation, Surgical, Laser & Procedural Considerations
  166. [166]

    Charlson ES, Sankar PS, Miller-Ellis E et al.. “The primary open-angle african american glaucoma genetics study: baseline demographics.” Ophthalmology (2015). PMID: 25576993 ↗

    L3OTHERCited in: Clinical Presentation, Ophthalmic Imaging and Functional Testing, History and Evolution of Treatment
  167. [167]

    Fujita A, Elze T, Zhao Y et al.. “Comparison of Glaucoma Surgery Incidence and Outcomes in Pseudoexfoliation and Primary Open-Angle Glaucoma: IRIS® Registry Analysis.” Ophthalmology (2025). PMID: 41015089 ↗

    L2OTHERCited in: Clinical Presentation, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  168. [168]

    Teo ZL, Soh ZD, Tham YC et al.. “Six-Year Incidence and Risk Factors for Primary Angle-Closure Disease: The Singapore Epidemiology of Eye Diseases Study.” Ophthalmology (2022). PMID: 35306094 ↗

    L2OTHERCited in: Clinical Presentation, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, Prevention, Screening & Surveillance
  169. [169]

    Aboobakar IF, Kinzy TG, Zhao Y et al.. “Mitochondrial TXNRD2 and ME3 Genetic Risk Scores Are Associated with Specific Primary Open-Angle Glaucoma Phenotypes.” Ophthalmology (2023). PMID: 36813040 ↗

    L3OTHERCited in: Clinical Presentation
  170. [170]

    Cheng HC, Guo CY, Chen MJ et al.. “Patient-reported vision-related quality of life differences between superior and inferior hemifield visual field defects in primary open-angle glaucoma.” JAMA ophthalmology (2015). PMID: 25429608 ↗

    L3OTHERCited in: Clinical Presentation
  171. [171]

    Budenz DL, Barton K, Whiteside-de Vos J et al.. “Prevalence of glaucoma in an urban West African population: the Tema Eye Survey.” JAMA ophthalmology (2013). PMID: 23538512 ↗

    L2OTHERCited in: Clinical Presentation, Prevention, Screening & Surveillance
  172. [172]

    Prager AJ, Hood DC, Liebmann JM et al.. “Association of Glaucoma-Related, Optical Coherence Tomography-Measured Macular Damage With Vision-Related Quality of Life.” JAMA ophthalmology (2017). PMID: 28594977 ↗

    L3OTHERCited in: Clinical Presentation, Ophthalmic Imaging and Functional Testing, History and Evolution of Treatment
  173. [173]

    Baskaran M, Foo RC, Cheng CY et al.. “The Prevalence and Types of Glaucoma in an Urban Chinese Population: The Singapore Chinese Eye Study.” JAMA ophthalmology (2015). PMID: 25974263 ↗

    L2OTHERCited in: Clinical Presentation, Acute & Vision-Threatening Management
  174. [174]

    Fox AR, Fingert JH. “Familial normal tension glaucoma genetics.” Progress in retinal and eye research (2023). PMID: 37353142 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute & Vision-Threatening Management, Prognosis & Natural History
  175. [175]

    O'Brien JM, Salowe RJ, Fertig R et al.. “Family History in the Primary Open-Angle African American Glaucoma Genetics Study Cohort.” American journal of ophthalmology (2018). PMID: 29555482 ↗

    L3OTHERCited in: Clinical Presentation, History and Evolution of Treatment
  176. [176]

    Topouzis F, Coleman AL, Harris A et al.. “Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study.” American journal of ophthalmology (2007). PMID: 18045565 ↗

    L2OTHERCited in: Clinical Presentation
  177. [177]

    Wu JH, Moghimi S, Nishida T et al.. “Association of macular OCT and OCTA parameters with visual acuity in glaucoma.” The British journal of ophthalmology (2022). PMID: 36126109 ↗

    L2OTHERCited in: Clinical Presentation
  178. [178]

    Belalcazar S, Tornero-Jimenez A, Mejia-Morales C et al.. “Assessment of the Effectiveness, Tolerability, and Safety of the Preservative-Free Fixed Combination of Timolol, Dorzolamide, and Brimonidine Compared to Separate Therapies in Patients with Glaucoma, a Randomized Controlled Trial.” Clinical ophthalmology (Auckland, N.Z.) (2026). PMID: 41737851 ↗

    L1RCTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Complications & Ocular Sequelae
  179. [179]

    Maheshwari D, Pillai MR, Grover DS et al.. “Two-Year Outcomes of Combined Phacoemulsification and Ab Interno Tanito Microhook Trabeculotomy in Open-Angle Glaucoma: A Prospective Randomized Trial.” Ophthalmology. Glaucoma (2025). PMID: 41407161 ↗

    L1RCTCited in: Clinical Presentation, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
  180. [180]

    Tanito M, Manabe SI, Hamanaka T et al.. “A case series of endoscopic cyclophotocoagulation with 532-nm laser in Japanese patients with refractory glaucoma.” Eye (London, England) (2019). PMID: 31332294 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Severity, Staging & Risk Stratification
  181. [181]

    Tanabe S, Yuki K, Ozeki N et al.. “The association between primary open-angle glaucoma and motor vehicle collisions.” Investigative ophthalmology & visual science (2011). PMID: 21447677 ↗

    L3OTHERCited in: Clinical Presentation, History and Evolution of Treatment
  182. [182]

    Maiello G, Kwon M. “Despite Impaired Binocular Function, Binocular Disparity Integration Across the Visual Field Is Spared in Normal Aging and Glaucoma.” Investigative ophthalmology & visual science (2023). PMID: 37129906 ↗

    L2OTHERCited in: Clinical Presentation
  183. [183]

    Liang YB, Friedman DS, Zhou Q et al.. “Prevalence of primary open angle glaucoma in a rural adult Chinese population: the Handan eye study.” Investigative ophthalmology & visual science (2011). PMID: 21896871 ↗

    L2OTHERCited in: Clinical Presentation
  184. [184]

    Kwon M, Liu R, Patel BN et al.. “Slow Reading in Glaucoma: Is it due to the Shrinking Visual Span in Central Vision?” Investigative ophthalmology & visual science (2017). PMID: 29131903 ↗

    L2OTHERCited in: Clinical Presentation
  185. [185]

    Lee JM, Caprioli J, Nouri-Mahdavi K et al.. “Baseline prognostic factors predict rapid visual field deterioration in glaucoma.” Investigative ophthalmology & visual science (2014). PMID: 24458154 ↗

    L2OTHERCited in: Clinical Presentation
  186. [186]

    Olvera-Montaño O, Mejia-Morales C, Jauregui-Franco RO et al.. “Maximum Tolerated Medical Therapy for Glaucoma: Fixed-Dose Combinations of Timolol, Dorzolamide, Brimonidine with Latanoprost Versus Timolol, Dorzolamide with Latanoprost.” Clinical ophthalmology (Auckland, N.Z.) (2025). PMID: 40873654 ↗

    L1TRIAL_NONRANDOMCited in: Clinical Presentation, Complications & Ocular Sequelae
  187. [187]

    Munaje MI, Aribaba OT, Atima MO et al.. “Phaco-trabeculectomy versus MSICS-trabeculectomy for coexisting cataract and glaucoma: visual and IOP outcomes from a randomized trial in Nigeria.” BMC ophthalmology (2025). PMID: 41194003 ↗

    L1RCTCited in: Clinical Presentation
  188. [188]

    Hirunpatravong P, Uramphorn N, Kasemsup T et al.. “Comparison of Preoperative Subconjunctival Injection, Intraoperative Subconjunctival Injection, and Soaked Sponges as Mitomycin C Delivery Methods for Trabeculectomy with a 6-Month Follow-Up Period: A Randomized Controlled Pilot Study.” Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics (2025). PMID: 41125397 ↗

    L1RCTCited in: Clinical Presentation
  189. [189]

    Lai ACK, Buchan JC, Chan JC et al.. “Determinants of late presentation of glaucoma in Hong Kong.” Eye (London, England) (2022). PMID: 36100709 ↗

    L3OTHERCited in: Clinical Presentation, Acute & Vision-Threatening Management
  190. [190]

    Yap TE, Zollet P, Husein S et al.. “Endocyclophotocoagulation combined with phacoemulsification in surgically naive primary open-angle glaucoma: three-year results.” Eye (London, England) (2021). PMID: 34526677 ↗

    L4OTHERCited in: Clinical Presentation, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  191. [191]

    Hsu ST, Lai YJ, Chan WC et al.. “Ocular decompression retinopathy after anterior chamber paracentesis - Case series and systematic review.” Taiwan journal of ophthalmology (2025). PMID: 41523125 ↗

    L4SR_OBSCited in: Clinical Presentation
  192. [192]

    Miyao K, Imazeki M, Oyama T et al.. “Efficacy of ripasudil-brimonidine fixed-dose combination in secondary glaucoma associated with uveitis: a retrospective study.” Japanese journal of ophthalmology (2026). PMID: 42018113 ↗

    L3COHORTCited in: Clinical Presentation
  193. [193]

    Gordon MO, Gao F, Burkland J et al.. “Quality of Life and Primary Open-Angle Glaucoma in the Ocular Hypertension Treatment Study.” JAMA ophthalmology (2024). PMID: 39207774 ↗

    L2RCTCited in: Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations
  194. [194]

    Li T, Lindsley K, Rouse B et al.. “Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.” Ophthalmology (2015). PMID: 26526633 ↗

    L1SR_OBSCited in: Clinical Examination and Diagnostic Workup, Prognosis & Natural History, Special Populations & Pregnancy
  195. [195]

    Gordon MO, Heuer DK, Higginbotham EJ et al.. “Visual Field Progression in the Ocular Hypertension Treatment Study.” American journal of ophthalmology (2024). PMID: 39647569 ↗

    L2RCTCited in: Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Special Populations & Pregnancy
  196. [196]

    Tanihara H, Yamamoto T, Aihara M et al.. “Ripasudil-Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials.” American journal of ophthalmology (2022). PMID: 36410471 ↗

    L1TRIAL_NONRANDOMCited in: Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy
  197. [197]

    Zhao D, Cho J, Kim MH et al.. “The association of blood pressure and primary open-angle glaucoma: a meta-analysis.” American journal of ophthalmology (2014). PMID: 24879946 ↗

    L2SR_OBSCited in: Clinical Examination and Diagnostic Workup
  198. [198]

    Hanyuda A, Goto A, Nakatochi M et al.. “Association Between Glycemic Traits and Primary Open-Angle Glaucoma: A Mendelian Randomization Study in the Japanese Population.” American journal of ophthalmology (2022). PMID: 36162535 ↗

    L2SR_OBSCited in: Clinical Examination and Diagnostic Workup
  199. [199]

    Liu Y, Gong D, Dang K et al.. “Diagnostic accuracy of next generation sequencing-based genetic research for primary glaucoma: A systematic review and meta-analysis.” Survey of ophthalmology (2025). PMID: 41043518 ↗

    L2SR_OBSCited in: Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management
  200. [200]

    Wang W, Zhang X. “Choroidal thickness and primary open-angle glaucoma: a cross-sectional study and meta-analysis.” Investigative ophthalmology & visual science (2014). PMID: 25168904 ↗

    L2SR_OBSCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
  201. [201]

    Medeiros FA, Malek DA, Tseng H et al.. “Short-term Detection of Fast Progressors in Glaucoma: The Fast Progression Assessment through Clustered Evaluation (Fast-PACE) Study.” Ophthalmology (2023). PMID: 38160883 ↗

    L2OTHERCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Long-term & Definitive Management
  202. [202]

    Suh MH, Weinreb RN, Walker E et al.. “Longitudinal Measurement of Optic Disc Vessel Density to Detect Glaucoma Progression in High Myopia.” Ophthalmology (2025). PMID: 40769299 ↗

    L4OTHERCited in: Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification
  203. [203]

    Sit AJ, Chen TC, Takusagawa HL et al.. “Corneal Hysteresis for the Diagnosis of Glaucoma and Assessment of Progression Risk: A Report by the American Academy of Ophthalmology.” Ophthalmology (2022). PMID: 36529572 ↗

    L2REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  204. [204]

    Kolovos A, Qassim A, Hassall MM et al.. “A Multitrait Open-Angle Glaucoma Polygenic Risk Score Stratifies Risk of Glaucoma Diagnosis and Severity in Eyes with Pseudoexfoliation.” Ophthalmology (2025). PMID: 40010646 ↗

    L3OTHERCited in: Clinical Examination and Diagnostic Workup, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  205. [205]

    Medeiros FA, Varma A, Jammal AA et al.. “Accelerated Epigenetic Aging Is Associated with Faster Glaucoma Progression: A DNA Methylation Study.” Ophthalmology (2024). PMID: 39716635 ↗

    L3OTHERCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
  206. [206]

    Pham K, Jin F, Lee R et al.. “Association between Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Use and Primary Open-Angle Glaucoma Risk in All of Us.” Ophthalmology (2025). PMID: 40550363 ↗

    L3OTHERCited in: Clinical Examination and Diagnostic Workup, History and Evolution of Treatment
  207. [207]

    Pinney EL, Ferreyra HA, Frohman L. “A curious case of glaucoma?” Survey of ophthalmology (2013). PMID: 23911153 ↗

    L4CASE_REPORTCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification
  208. [208]

    Fan R, Bowd C, Christopher M et al.. “Detecting Glaucoma in the Ocular Hypertension Study Using Deep Learning.” JAMA ophthalmology (2022). PMID: 35297959 ↗

    L3OTHERCited in: Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Special Populations & Pregnancy
  209. [209]

    Mroczkowska S, Benavente-Perez A, Negi A et al.. “Primary open-angle glaucoma vs normal-tension glaucoma: the vascular perspective.” JAMA ophthalmology (2013). PMID: 22964974 ↗

    L3OTHERCited in: Clinical Examination and Diagnostic Workup
  210. [210]

    Simcoe MJ, Weisschuh N, Wissinger B et al.. “Genetic Heritability of Pigmentary Glaucoma and Associations With Other Eye Phenotypes.” JAMA ophthalmology (2020). PMID: 31999318 ↗

    L3OTHERCited in: Clinical Examination and Diagnostic Workup
  211. [211]

    Philip S, Najafi A, Tantraworasin A et al.. “Nailfold Capillaroscopy of Resting Peripheral Blood Flow in Exfoliation Glaucoma and Primary Open-Angle Glaucoma.” JAMA ophthalmology (2019). PMID: 30973595 ↗

    L3OTHERCited in: Clinical Examination and Diagnostic Workup, History and Evolution of Treatment
  212. [212]

    Duncan RO, Sample PA, Weinreb RN et al.. “Retinotopic organization of primary visual cortex in glaucoma: Comparing fMRI measurements of cortical function with visual field loss.” Progress in retinal and eye research (2006). PMID: 17126063 ↗

    L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
  213. [213]

    Caprioli J, Coleman AL. “Blood pressure, perfusion pressure, and glaucoma.” American journal of ophthalmology (2010). PMID: 20399924 ↗

    L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification
  214. [214]

    Rao HL, Sreenivasaiah S, Riyazuddin M et al.. “Choroidal Microvascular Dropout in Primary Angle Closure Glaucoma.” American journal of ophthalmology (2018). PMID: 30552893 ↗

    L3OTHERCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  215. [215]

    Nishida T, Oh WH, Moghimi S et al.. “Central macular OCTA parameters in glaucoma.” The British journal of ophthalmology (2021). PMID: 34426401 ↗

    L3OTHERCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
  216. [216]

    Micheletti E, Moghimi S, Nishida T et al.. “Factors associated with choroidal microvascular dropout change.” The British journal of ophthalmology (2022). PMID: 35803672 ↗

    L3OTHERCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
  217. [217]

    Cousins CC, Chou JC, Greenstein SH et al.. “Resting nailfold capillary blood flow in primary open-angle glaucoma.” The British journal of ophthalmology (2018). PMID: 29699986 ↗

    L3OTHERCited in: Clinical Examination and Diagnostic Workup
  218. [218]

    Aihara M. “Phase III Prospective Randomised Study of Netarsudil and Concomitant Latanoprost Efficacy and Safety for Primary Open-Angle Glaucoma or Ocular Hypertension in Japan: J-ROCKET-2.” Advances in therapy (2026). PMID: 41915113 ↗

    L1RCTCited in: Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
  219. [219]

    Selvan H, Gupta S, Wiggs JL et al.. “Juvenile-onset open-angle glaucoma - A clinical and genetic update.” Survey of ophthalmology (2021). PMID: 34536459 ↗

    L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  220. [220]

    Lim YJ, Bang JW, Weinreb RN et al.. “Temporal Optic Disc Microvasculature Dropout in Glaucoma.” Investigative ophthalmology & visual science (2023). PMID: 37540177 ↗

    L4OTHERCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
  221. [221]

    Riina N, Harris A, Siesky BA et al.. “Using Multi-Layer Perceptron Driven Diagnosis to Compare Biomarkers for Primary Open Angle Glaucoma.” Investigative ophthalmology & visual science (2024). PMID: 39250119 ↗

    L3OTHERCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
  222. [222]

    Olafsdottir OB, Hardarson SH, Gottfredsdottir MS et al.. “Retinal oximetry in primary open-angle glaucoma.” Investigative ophthalmology & visual science (2011). PMID: 21715353 ↗

    L4OTHERCited in: Clinical Examination and Diagnostic Workup, Special Populations & Pregnancy
  223. [223]

    Kim J, Kang JH, Wiggs JL et al.. “Does Age Modify the Relation Between Genetic Predisposition to Glaucoma and Various Glaucoma Traits in the UK Biobank?” Investigative ophthalmology & visual science (2025). PMID: 39982391 ↗

    L4OTHERCited in: Clinical Examination and Diagnostic Workup, Prevention, Screening & Surveillance
  224. [224]

    Khawaja AP, Viswanathan AC. “Are we ready for genetic testing for primary open-angle glaucoma?” Eye (London, England) (2018). PMID: 29379103 ↗

    L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management
  225. [225]

    Garg A, Gazzard G. “Treatment choices for newly diagnosed primary open angle and ocular hypertension patients.” Eye (London, England) (2019). PMID: 31685971 ↗

    L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Special Populations & Pregnancy
  226. [226]

    Scheres LMJ, Kujovic-Aleksov S, Winkens B et al.. “Five-year follow-up with the PreserFlo MicroShunt for open-angle glaucoma.” Eye (London, England) (2025). PMID: 39979610 ↗

    L4OTHERCited in: Clinical Examination and Diagnostic Workup, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  227. [227]

    Cackett P, Vallance J, Cobb C et al.. “South-East Scotland trabeculectomy survey.” Eye (London, England) (2005). PMID: 16215540 ↗

    L4OTHERCited in: Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  228. [228]

    Doozandeh A, Hatami M, Khorrami Z et al.. “Early Diagnosis of Glaucoma By Optical Coherence Tomography: A Systematic Review and Network Meta-analysis.” Journal of ophthalmic & vision research (2026). PMID: 41815442 ↗

    L3SR_OBSCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Surgical, Laser & Procedural Considerations
  229. [229]

    Sun W, Zhang L, Yang W et al.. “[Longsha Kaihe Liuqi acupuncture in treatment of primary open angle glaucoma: a randomized controlled trial].” Zhongguo zhen jiu = Chinese acupuncture & moxibustion (2025). PMID: 41839594 ↗

    L1RCTCited in: Clinical Examination and Diagnostic Workup, Long-term & Definitive Management
  230. [230]

    Tsai CY, Weng CH, Sheen YJ et al.. “Association between probiotic prescriptions and the incidence of primary open-angle glaucoma in patients with documented dry eye.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026). PMID: 42397591 ↗

    L2OTHERCited in: Clinical Examination and Diagnostic Workup
  231. [231]

    Suh MH, Zangwill LM, Manalastas PI et al.. “Optical Coherence Tomography Angiography Vessel Density in Glaucomatous Eyes with Focal Lamina Cribrosa Defects.” Ophthalmology (2016). PMID: 27592175 ↗

    L3TRIAL_NONRANDOMCited in: Ophthalmic Imaging and Functional Testing
  232. [232]

    Lin C, Mak H, Yu M et al.. “Trend-Based Progression Analysis for Examination of the Topography of Rates of Retinal Nerve Fiber Layer Thinning in Glaucoma.” JAMA ophthalmology (2017). PMID: 28152147 ↗

    L2TRIAL_NONRANDOMCited in: Ophthalmic Imaging and Functional Testing, Prognosis & Natural History
  233. [233]

    Choi YJ, Lee EJ, Kim BH et al.. “Microstructure of the optic disc pit in open-angle glaucoma.” Ophthalmology (2014). PMID: 25037753 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  234. [234]

    Kim CS, Seong GJ, Lee NH et al.. “Prevalence of primary open-angle glaucoma in central South Korea the Namil study.” Ophthalmology (2011). PMID: 21269703 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing, Prevention, Screening & Surveillance
  235. [235]

    Kim M, Kim TW, Weinreb RN et al.. “Differentiation of parapapillary atrophy using spectral-domain optical coherence tomography.” Ophthalmology (2013). PMID: 23672970 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  236. [236]

    Ha A, Kim TJ, Girard MJA et al.. “Baseline Lamina Cribrosa Curvature and Subsequent Visual Field Progression Rate in Primary Open-Angle Glaucoma.” Ophthalmology (2018). PMID: 29945800 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing
  237. [237]

    Nolan WP, See JL, Chew PT et al.. “Detection of primary angle closure using anterior segment optical coherence tomography in Asian eyes.” Ophthalmology (2006). PMID: 17070597 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  238. [238]

    Nishida T, Moghimi S, Wu JH et al.. “Association of Initial Optical Coherence Tomography Angiography Vessel Density Loss With Faster Visual Field Loss in Glaucoma.” JAMA ophthalmology (2022). PMID: 35201270 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing
  239. [239]

    Chen RI, Barbosa DT, Hsu CH et al.. “Ethnic differences in trabecular meshwork height by optical coherence tomography.” JAMA ophthalmology (2015). PMID: 25634557 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  240. [240]

    Siggs OM, Qassim A, Han X et al.. “Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma.” JAMA ophthalmology (2022). PMID: 36355370 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing, Complications & Ocular Sequelae, Prevention, Screening & Surveillance
  241. [241]

    Lee WJ, Kim TJ, Kim YK et al.. “Serial Combined Wide-Field Optical Coherence Tomography Maps for Detection of Early Glaucomatous Structural Progression.” JAMA ophthalmology (2018). PMID: 30054615 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing
  242. [242]

    Choi JA, Park HY, Shin HY et al.. “Optic disc characteristics in patients with glaucoma and combined superior and inferior retinal nerve fiber layer defects.” JAMA ophthalmology (2014). PMID: 24921983 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  243. [243]

    Tansuebchueasai N, Nishida T, Moghimi S et al.. “Rate of Initial Optic Nerve Head Capillary Density Loss and Risk of Visual Field Progression.” JAMA ophthalmology (2024). PMID: 38696186 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing
  244. [244]

    Lee SH, Lee EJ, Kim TW. “Structural characteristics of the acquired optic disc pit and the rate of progressive retinal nerve fiber layer thinning in primary open-angle glaucoma.” JAMA ophthalmology (2015). PMID: 26247160 ↗

    L3OTHERCited in: Ophthalmic Imaging and Functional Testing
  245. [245]

    Tun TA, Atalay E, Baskaran M et al.. “Association of Functional Loss With the Biomechanical Response of the Optic Nerve Head to Acute Transient Intraocular Pressure Elevations.” JAMA ophthalmology (2018). PMID: 29302683 ↗

    L3OTHERCited in: Ophthalmic Imaging and Functional Testing, Acute & Vision-Threatening Management
  246. [246]

    Hou H, Moghimi S, Zangwill LM et al.. “Macula Vessel Density and Thickness in Early Primary Open-Angle Glaucoma.” American journal of ophthalmology (2018). PMID: 30496723 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  247. [247]

    Miki A, Araie M, Leung CKS et al.. “Effects of Optic Nerve Head Structures on Retinal Nerve Fiber Layer Defects in Primary Open Angle Glaucoma Eyes: Analyses Using Retinal Optical Texture Analysis.” American journal of ophthalmology (2026). PMID: 41633416 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  248. [248]

    Rao HL, Dasari S, Puttaiah NK et al.. “Optical Microangiography and Progressive Retinal Nerve Fiber Layer Loss in Primary Open Angle Glaucoma.” American journal of ophthalmology (2021). PMID: 34320375 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  249. [249]

    Rao HL, Dasari S, Puttaiah NK et al.. “Optical Microangiography and Progressive Ganglion Cell-Inner Plexiform Layer Loss in Primary Open-Angle Glaucoma.” American journal of ophthalmology (2021). PMID: 34902324 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  250. [250]

    Suh MH, Jung DH, Weinreb RN et al.. “Optic Disc Microvasculature Dropout in Glaucoma Detected by Swept-Source Optical Coherence Tomography Angiography.” American journal of ophthalmology (2021). PMID: 34740630 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  251. [251]

    KhalafAllah MT, Zangwill LM, Proudfoot J et al.. “Racial Differences in Diagnostic Accuracy of Retinal Nerve Fiber Layer Thickness in Primary Open-Angle Glaucoma.” American journal of ophthalmology (2023). PMID: 38708401 ↗

    L3OTHERCited in: Ophthalmic Imaging and Functional Testing
  252. [252]

    Won HJ, Sung KR, Shin JW et al.. “Comparison of Lamina Cribrosa Curvature in Pseudoexfoliation and Primary Open-Angle Glaucoma.” American journal of ophthalmology (2020). PMID: 32971024 ↗

    L3OTHERCited in: Ophthalmic Imaging and Functional Testing
  253. [253]

    Kamalipour A, Moghimi S, Hou H et al.. “Multilayer Macula Vessel Density and Visual Field Progression in Glaucoma.” American journal of ophthalmology (2021). PMID: 34801510 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification
  254. [254]

    Chen A, Wei P, Wang J et al.. “Glaucomatous Focal Perfusion Loss in the Macula Measured by Optical Coherence Tomographic Angiography.” American journal of ophthalmology (2024). PMID: 39009239 ↗

    L3OTHERCited in: Ophthalmic Imaging and Functional Testing
  255. [255]

    Kleerekooper I, Wagner SK, Trip SA et al.. “Differentiating glaucoma from chiasmal compression using optical coherence tomography: the macular naso-temporal ratio.” The British journal of ophthalmology (2024). PMID: 37385651 ↗

    L3OTHERCited in: Ophthalmic Imaging and Functional Testing
  256. [256]

    Nishida T, Moghimi S, Hou H et al.. “Long-term reproducibility of optical coherence tomography angiography in healthy and stable glaucomatous eyes.” The British journal of ophthalmology (2021). PMID: 34933897 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing, Prognosis & Natural History
  257. [257]

    Lin F, Qiu Z, Li F et al.. “Macular and submacular choroidal microvasculature in patients with primary open-angle glaucoma and high myopia.” The British journal of ophthalmology (2021). PMID: 34893473 ↗

    L3OTHERCited in: Ophthalmic Imaging and Functional Testing
  258. [258]

    Pang R, Peng J, Cao K et al.. “Association between contrast sensitivity function and structural damage in primary open-angle glaucoma.” The British journal of ophthalmology (2024). PMID: 37423645 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification
  259. [259]

    Kang JM, Jammal AA, Medeiros FA. “Association between statin use and rates of structural and functional loss in glaucoma.” The British journal of ophthalmology (2022). PMID: 35537803 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing, History and Evolution of Treatment, Special Populations & Pregnancy
  260. [260]

    Nishida T, Moghimi S, Walker E et al.. “Association of foveal avascular zone change and glaucoma progression.” The British journal of ophthalmology (2024). PMID: 38164585 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification
  261. [261]

    Kim JA, Lee EJ, Kim TW. “Impact of peripapillary retinoschisis on visual field test results in glaucomatous eyes.” The British journal of ophthalmology (2022). PMID: 35728936 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  262. [262]

    Micheletti E, Moghimi S, El-Nimri N et al.. “Relationship of macular ganglion cell complex thickness to choroidal microvasculature drop-out in primary open-angle glaucoma.” The British journal of ophthalmology (2022). PMID: 35027356 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  263. [263]

    Dul M, Ennis R, Radner S et al.. “Retinal adaptation abnormalities in primary open-angle glaucoma.” Investigative ophthalmology & visual science (2015). PMID: 25613950 ↗

    L3OTHERCited in: Ophthalmic Imaging and Functional Testing
  264. [264]

    Wong D, Chua J, Lin E et al.. “Focal Structure-Function Relationships in Primary Open-Angle Glaucoma Using OCT and OCT-A Measurements.” Investigative ophthalmology & visual science (2020). PMID: 33372979 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  265. [265]

    Lee EJ, Han DK, Roh YJ et al.. “Underlying Microstructure of the Lamina Cribrosa at the Site of Microvasculature Dropout.” Investigative ophthalmology & visual science (2024). PMID: 39078730 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  266. [266]

    Berry EC, Marshall HN, Mullany S et al.. “Physical Activity Is Associated With Macular Thickness: A Multi-Cohort Observational Study.” Investigative ophthalmology & visual science (2023). PMID: 36867133 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing
  267. [267]

    Ha A, Kim YK, Baek SU et al.. “Optic Disc Microhemorrhage in Primary Open-Angle Glaucoma: Clinical Implications for Visual Field Progression.” Investigative ophthalmology & visual science (2019). PMID: 31042788 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing, Prognosis & Natural History
  268. [268]

    Katarya K, de Vries VA, Barbosa-Breda J et al.. “Prognostic factors of optical coherence tomography angiography in intermediate and advanced primary open-angle glaucoma: A systematic review and meta-analysis.” Acta ophthalmologica (2026). PMID: 41615222 ↗

    L1SR_OBSCited in: Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Prognosis & Natural History
  269. [269]

    Yenice O, Temel A, Orüm O. “The effect of artificial tear administration on visual field testing in patients with glaucoma and dry eye.” Eye (London, England) (2006). PMID: 16440009 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  270. [270]

    Jing D, Liu Z, Chou Y et al.. “Discrepancy between NTG and POAG with corneal nerves in CCM.” Eye (London, England) (2021). PMID: 34341486 ↗

    L3OTHERCited in: Ophthalmic Imaging and Functional Testing
  271. [271]

    Fan YY, Su WW, Liu CH et al.. “Correlation between structural progression in glaucoma and obstructive sleep apnea.” Eye (London, England) (2019). PMID: 30971813 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification
  272. [272]

    Papadia M, Sofianos C, Iester M et al.. “Corneal thickness and visual field damage in glaucoma patients.” Eye (London, England) (2006). PMID: 16645628 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  273. [273]

    Özyol P, Özyol E, Günel-Karadeniz P. “Evaluation of vessel density in healthy subjects with family history of glaucoma.” Eye (London, England) (2022). PMID: 35013608 ↗

    L3OTHERCited in: Ophthalmic Imaging and Functional Testing, History and Evolution of Treatment
  274. [274]

    Sato T, Kawaji T, Hirata A. “Transient ciliochoroidal detachment after 360-degree suture trabeculotomy ab interno for open-angle glaucoma: 12-month follow-up.” Eye (London, England) (2019). PMID: 30792522 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  275. [275]

    Sihota R, Srinivasan G, Dada T et al.. “Is the ISNT rule violated in early primary open-angle glaucoma--a scanning laser tomography study.” Eye (London, England) (2007). PMID: 17435693 ↗

    L3OTHERCited in: Ophthalmic Imaging and Functional Testing
  276. [276]

    Bak E, Lee WJ, Kim JS et al.. “Deep optic nerve head morphology and glaucoma progression in eyes with and without laminar dot sign: a longitudinal comparative study.” Eye (London, England) (2020). PMID: 32499586 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing
  277. [277]

    Huang Z, Su K, Zhou L et al.. “Systemic inflammatory biomarkers as risk factors for age-related ocular diseases: a large-scale prospective cohort study.” The British journal of ophthalmology (2026). PMID: 42091216 ↗

    L2COHORTCited in: Ophthalmic Imaging and Functional Testing, Surgical, Laser & Procedural Considerations
  278. [278]

    Wang J, Wang S, Chen Z et al.. “Surgical management of primary open-angle glaucoma in Central China: A 6-year retrospective cohort study.” Medicine (2025). PMID: 41204569 ↗

    L2COHORTCited in: Ophthalmic Imaging and Functional Testing
  279. [279]

    Hug SC, Fiore C, Shang X et al.. “Does trabeculectomy work equally well in different types of glaucoma? A single-center, retrospective, comparative cohort study.” Journal francais d'ophtalmologie (2025). PMID: 41175719 ↗

    L2COHORTCited in: Ophthalmic Imaging and Functional Testing
  280. [280]

    Uzel MM, Yiğit Y, Girgin Y et al.. “Effect of Optic Disc Size on Retinal Nerve Fiber Layer Thickness and Peripapillary Vascular Density in Advanced Primary Open-Angle Glaucoma.” Journal of glaucoma (2026). PMID: 42384721 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  281. [281]

    Canleblebici M, Erdağ M, Dal A. “Optical Coherence Tomography-Derived Excavation Index and Structure-Function Damage in Glaucoma.” Journal of glaucoma (2026). PMID: 42384717 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  282. [282]

    Zhou DB, Jammal AA, Donkor R et al.. “Association between 24-Hour Blood Pressure and Rates of Retinal Nerve Fiber Layer Progression in Glaucoma: The Vascular Imaging in Glaucoma Study.” American journal of ophthalmology (2026). PMID: 42323976 ↗

    L2OTHERCited in: Ophthalmic Imaging and Functional Testing
  283. [283]

    Lee SH, Seo JH, Moon GY et al.. “Structural Characteristics of Parapapillary Choroidal Microvasculature Dropout in Primary Open-Angle Glaucoma: Comparison Between Width and Area.” Clinical ophthalmology (Auckland, N.Z.) (2026). PMID: 42272752 ↗

    L4OTHERCited in: Ophthalmic Imaging and Functional Testing
  284. [284]

    Waksmunski AR, Kinzy TG, Cruz LA et al.. “Glaucoma Genetic Risk Scores in the Million Veteran Program.” Ophthalmology (2022). PMID: 35718050 ↗

    L2SR_OBSCited in: Severity, Staging & Risk Stratification, Prevention, Screening & Surveillance
  285. [285]

    Dueker DK, Singh K, Lin SC et al.. “Corneal thickness measurement in the management of primary open-angle glaucoma: a report by the American Academy of Ophthalmology.” Ophthalmology (2007). PMID: 17822980 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Prevention, Screening & Surveillance
  286. [286]

    Seol BR, Park KH, Jeoung JW. “Optic Disc Tilt and Glaucoma Progression in Myopic Glaucoma: A Longitudinal Match-Pair Case-Control Study.” Investigative ophthalmology & visual science (2019). PMID: 31099829 ↗

    L3CASE_CONTROLCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
  287. [287]

    Choquet H, Khawaja AP, Jiang C et al.. “Association Between Myopic Refractive Error and Primary Open-Angle Glaucoma: A 2-Sample Mendelian Randomization Study.” JAMA ophthalmology (2022). PMID: 35900730 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Prevention, Screening & Surveillance
  288. [288]

    Siggs OM, Han X, Qassim A et al.. “Association of Monogenic and Polygenic Risk With the Prevalence of Open-Angle Glaucoma.” JAMA ophthalmology (2021). PMID: 34264281 ↗

    L4OTHERCited in: Severity, Staging & Risk Stratification
  289. [289]

    Vass C, Hirn C, Sycha T et al.. “Medical interventions for primary open angle glaucoma and ocular hypertension.” The Cochrane database of systematic reviews (2007). PMID: 17943780 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification, Special Populations & Pregnancy
  290. [290]

    Gunasegaran G, Moghimi S, Walker E et al.. “Differential Impact of Central and Global Visual Field Progression on Quality of Life in Glaucoma.” American journal of ophthalmology (2025). PMID: 40334725 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  291. [291]

    Kim H, Jang H, Bae HW et al.. “Impact of epiretinal membrane surgery on glaucoma progression: influence of glaucoma severity and internal limiting membrane peeling.” The British journal of ophthalmology (2026). PMID: 41338942 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  292. [292]

    Tan JK, Steel DH, Ahmad S et al.. “Exploring the potential of rho kinase inhibitors in ophthalmology: From mechanisms to clinical practice.” Survey of ophthalmology (2025). PMID: 40250716 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Special Populations & Pregnancy
  293. [293]

    Pasquale LR, Hanyuda A, Ren A et al.. “Nailfold Capillary Abnormalities in Primary Open-Angle Glaucoma: A Multisite Study.” Investigative ophthalmology & visual science (2015). PMID: 26523386 ↗

    L3OTHERCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  294. [294]

    Karthikeyan SK, McKendrick AM, Pai VH et al.. “Contrast Discrimination and Global Form Perception in Primary Open-Angle Glaucoma and Primary Angle-Closure Glaucoma.” Investigative ophthalmology & visual science (2024). PMID: 38771569 ↗

    L4OTHERCited in: Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  295. [295]

    Lee JY, Sung KR, Han S et al.. “Effect of myopia on the progression of primary open-angle glaucoma.” Investigative ophthalmology & visual science (2015). PMID: 25698704 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  296. [296]

    Nair AP, Tejwani S, Dinakaran S et al.. “Elevated Neurodegeneration Markers in the Aqueous Humor of Primary Open Angle and Normal Tension Glaucoma Patients Correlate With Disease Severity.” Investigative ophthalmology & visual science (2025). PMID: 41091002 ↗

    L3OTHERCited in: Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management
  297. [297]

    Songel-Sanchis B, Morales-Fernández L, García-Bardera J et al.. “The Ocular and Gut Microbiome Axis in Understanding Glaucoma: A Systematic Review.” Journal of clinical medicine (2026). PMID: 41682924 ↗

    L5SR_OBSCited in: Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  298. [298]

    Rossetti L, Goni F, Denis P et al.. “Focusing on glaucoma progression and the clinical importance of progression rate measurement: a review.” Eye (London, England) (2010). PMID: 20944656 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment
  299. [299]

    Tan CQL, Tan CJ, Tai BC et al.. “Longitudinal Association Between Disc Hemorrhage and Primary Open-Angle Glaucoma Progression: A Systematic Review and Meta-Analysis.” Ophthalmic epidemiology (2026). PMID: 41626848 ↗

    L2SR_OBSCited in: Severity, Staging & Risk Stratification
  300. [300]

    Prum BE, Rosenberg LF, Gedde SJ et al.. “Primary Open-Angle Glaucoma Preferred Practice Pattern(®) Guidelines.” Ophthalmology (2015). PMID: 26581556 ↗

    L1GUIDELINECited in: Acute & Vision-Threatening Management, History and Evolution of Treatment
  301. [301]

    Prum BE, Lim MC, Mansberger SL et al.. “Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern(®) Guidelines.” Ophthalmology (2015). PMID: 26581560 ↗

    L1GUIDELINECited in: Acute & Vision-Threatening Management, History and Evolution of Treatment
  302. [302]

    Soh Z, Yu M, Betzler BK et al.. “The Global Extent of Undetected Glaucoma in Adults: A Systematic Review and Meta-analysis.” Ophthalmology (2021). PMID: 33865875 ↗

    L1SR_OBSCited in: Acute & Vision-Threatening Management
  303. [303]

    Asefa NG, Neustaeter A, Jansonius NM et al.. “Heritability of glaucoma and glaucoma-related endophenotypes: Systematic review and meta-analysis.” Survey of ophthalmology (2019). PMID: 31229521 ↗

    L1SR_OBSCited in: Acute & Vision-Threatening Management
  304. [304]

    Pham K, Salowe R, Di Rosa I et al.. “The Association between Glaucoma and Dementia in a National Cohort of All of Us Participants.” Ophthalmology (2025). PMID: 40961986 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management
  305. [305]

    Ige MO, French DD, Chaudhury AS et al.. “Quality of Care in Patients With Newly Diagnosed Glaucoma.” JAMA ophthalmology (2025). PMID: 40965904 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
  306. [306]

    Kanu LN, Jang I, Oh DJ et al.. “Glaucoma Care of Prison Inmates at an Academic Hospital.” JAMA ophthalmology (2020). PMID: 32077908 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
  307. [307]

    Newman-Casey PA, Talwar N, Nan B et al.. “The potential association between postmenopausal hormone use and primary open-angle glaucoma.” JAMA ophthalmology (2014). PMID: 24481323 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
  308. [308]

    Realini T. “Selective laser trabeculoplasty for the management of open-angle glaucoma in St. Lucia.” JAMA ophthalmology (2013). PMID: 23348420 ↗

    L4OTHERCited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
  309. [309]

    Kass MA, Heuer DK, Higginbotham EJ et al.. “Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up.” JAMA ophthalmology (2021). PMID: 33856434 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
  310. [310]

    Gordon MO, Kass MA. “What We Have Learned From the Ocular Hypertension Treatment Study.” American journal of ophthalmology (2018). PMID: 29501371 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
  311. [311]

    Hong AT, Lin F, Baxter S et al.. “Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.” American journal of ophthalmology (2025). PMID: 41360342 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management
  312. [312]

    Casson RJ, Newland HS, Muecke J et al.. “Prevalence of glaucoma in rural Myanmar: the Meiktila Eye Study.” The British journal of ophthalmology (2007). PMID: 17510475 ↗

    L2REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Prevention, Screening & Surveillance
  313. [313]

    Suwan Y, Aghsaei Fard M, Vilainerun N et al.. “Parapapillary choroidal microvascular density in acute primary angle-closure and primary open-angle glaucoma: an optical coherence tomography angiography study.” The British journal of ophthalmology (2022). PMID: 35831203 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management
  314. [314]

    Fujiwara K, Ueda E, Hata J et al.. “Association between corneal hysteresis and glaucoma in a Japanese population: the Hisayama Study.” The British journal of ophthalmology (2024). PMID: 38471749 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management
  315. [315]

    Salim S, Shields MB. “Glaucoma and systemic diseases.” Survey of ophthalmology (2010). PMID: 19833365 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Special Populations & Pregnancy
  316. [316]

    Dow E, Kearney S, Day M. “Absolute Risks and Decision Tools for Communicating the Risks of Visual Impairment From Myopia-Related Diseases.” Investigative ophthalmology & visual science (2025). PMID: 40305470 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
  317. [317]

    Yuan J, Cui X, Yu-Wai-Man P et al.. “Integrative Proteogenomic Analysis Identifies Genetically Supported Plasma Proteins, Metabolites, and Pathways in Glaucoma.” Investigative ophthalmology & visual science (2026). PMID: 41649226 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management
  318. [318]

    Abu-Amero KK, Morales J, Osman MN et al.. “Nuclear and mitochondrial analysis of patients with primary angle-closure glaucoma.” Investigative ophthalmology & visual science (2007). PMID: 18055808 ↗

    L4OTHERCited in: Acute & Vision-Threatening Management
  319. [319]

    Narayanaswamy A, Nai MH, Nongpiur ME et al.. “Young's Modulus Determination of Normal and Glaucomatous Human Iris.” Investigative ophthalmology & visual science (2019). PMID: 31242291 ↗

    L3OTHERCited in: Acute & Vision-Threatening Management
  320. [320]

    Jerrome S, Niranjana B, Joseph S et al.. “Prevalence of Glaucoma in India over 2 Decades and Projections to 2050: A Systematic Review and Meta-Analysis.” Ophthalmology. Glaucoma (2026). PMID: 41534595 ↗

    L1SR_OBSCited in: Acute & Vision-Threatening Management, Prevention, Screening & Surveillance
  321. [321]

    Hitchings RA. “Glaucoma: an area of darkness.” Eye (London, England) (2008). PMID: 18791552 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, History and Evolution of Treatment
  322. [322]

    Chou CC, Lu YA, Weng CH et al.. “The association between antiglaucomatous agents and Alzheimer's disease.” Eye (London, England) (2024). PMID: 39341977 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management
  323. [323]

    Shemesh N, Nitzan I, Kubovsky S et al.. “Risk of retinal artery occlusion in patients with primary open-angle glaucoma: a retrospective cohort study.” International journal of retina and vitreous (2026). PMID: 41872918 ↗

    L2COHORTCited in: Acute & Vision-Threatening Management, Prognosis & Natural History
  324. [324]

    Marin A, Quintero MA, Kaplan TM et al.. “Evaluation of tube extender use in glaucoma management: insights from a cohort study.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026). PMID: 41860598 ↗

    L2COHORTCited in: Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  325. [325]

    Liu DY, Kuo HT, Hsu AY et al.. “Risk of Glaucoma in Patients With Idiopathic Noninfectious Uveitis: A Multi-Institutional Real-World Retrospective Cohort Study.” American journal of ophthalmology (2026). PMID: 41592690 ↗

    L2COHORTCited in: Acute & Vision-Threatening Management, Prevention, Screening & Surveillance
  326. [326]

    Panarelli JF, Moster MR, Garcia-Feijoo J et al.. “Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: Two-Year Results from a Randomized, Multicenter Study.” Ophthalmology (2023). PMID: 37769852 ↗

    L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Special Populations & Pregnancy
  327. [327]

    Casson RJ, Han G, Ebneter A et al.. “Glucose-induced temporary visual recovery in primary open-angle glaucoma: a double-blind, randomized study.” Ophthalmology (2014). PMID: 24491639 ↗

    L1RCTCited in: Long-term & Definitive Management, Special Populations & Pregnancy
  328. [328]

    Tanihara H, Inoue T, Yamamoto T et al.. “Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.” JAMA ophthalmology (2015). PMID: 25880207 ↗

    L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
  329. [329]

    Zhang ML, Chon BH, Wang J et al.. “Single vs multiple intraocular pressure measurements in glaucoma surgical trials.” JAMA ophthalmology (2014). PMID: 24831204 ↗

    L2RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
  330. [330]

    Hsia Y, Wang C, Su CC et al.. “Efficacy and Drug Interactions of Glaucoma Medications: A Systematic Review and Component Network Meta-analysis.” Ophthalmology (2025). PMID: 40701331 ↗

    L1SR_OBSCited in: Long-term & Definitive Management, Special Populations & Pregnancy
  331. [331]

    Webers CA, van der Valk R, Schouten JS et al.. “Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials.” Ophthalmology (2006). PMID: 17070584 ↗

    L1SR_OBSCited in: Long-term & Definitive Management
  332. [332]

    Stewart WC, Konstas AG, Nelson LA et al.. “Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.” Ophthalmology (2008). PMID: 18082886 ↗

    L1SR_OBSCited in: Long-term & Definitive Management, Prognosis & Natural History, Special Populations & Pregnancy
  333. [333]

    Ahmed IIK, Sheybani A, De Francesco T et al.. “Long-Term Endothelial Safety Profile With iStent Inject in Patients With Open-Angle Glaucoma.” American journal of ophthalmology (2023). PMID: 36868339 ↗

    L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History, Prevention, Screening & Surveillance
  334. [334]

    Aihara M, Lu F, Kawata H et al.. “Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.” American journal of ophthalmology (2020). PMID: 32533949 ↗

    L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
  335. [335]

    Kahook MY. “Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study.” American journal of ophthalmology (2010). PMID: 20570237 ↗

    L1RCTCited in: Long-term & Definitive Management
  336. [336]

    Grieshaber MC, Pienaar A, Olivier J et al.. “Canaloplasty for primary open-angle glaucoma: long-term outcome.” The British journal of ophthalmology (2010). PMID: 20962352 ↗

    L4RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  337. [337]

    Goyal S, Beltran-Agullo L, Rashid S et al.. “Effect of primary selective laser trabeculoplasty on tonographic outflow facility: a randomised clinical trial.” The British journal of ophthalmology (2010). PMID: 20472748 ↗

    L1RCTCited in: Long-term & Definitive Management
  338. [338]

    Niyadurupola N, Brodie J, Patel T et al.. “Topical prostaglandin analogue use and cystoid macular oedema following uneventful cataract surgery: a randomised control trial.” The British journal of ophthalmology (2021). PMID: 34045222 ↗

    L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Special Populations & Pregnancy
  339. [339]

    Chakrabarty S, Kader MA, Maheshwari D et al.. “Short-term outcomes of Mitomycin-C augmented phaco-trabeculectomy using subconjunctival injections versus soaked sponges: a randomized controlled trial.” Eye (London, England) (2023). PMID: 38057560 ↗

    L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
  340. [340]

    Martinez A, Sanchez M. “Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients.” Eye (London, England) (2008). PMID: 18535605 ↗

    L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae, Special Populations & Pregnancy
  341. [341]

    Enoch J, Jones L, Taylor DJ et al.. “How do different lighting conditions affect the vision and quality of life of people with glaucoma? A systematic review.” Eye (London, England) (2019). PMID: 31822854 ↗

    L2SR_OBSCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  342. [342]

    Elhusseiny AM, Eleiwa TK, Darwich R et al.. “Association Between Chronic Oral Nitrate Use and the Risk of Ocular Hypertension and Open-Angle Glaucoma.” American journal of ophthalmology (2025). PMID: 40684969 ↗

    L2OTHERCited in: Long-term & Definitive Management
  343. [343]

    Mansukhani SA, Barkmeier AJ, Bakri SJ et al.. “The Risk of Primary Open-Angle Glaucoma Following Vitreoretinal Surgery-A Population-based Study.” American journal of ophthalmology (2018). PMID: 29940165 ↗

    L2OTHERCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  344. [344]

    Hamanaka T, Sakurai T, Kato T et al.. “Quantitative Evaluation of Trabecular Meshwork in Normal Tension Glaucoma Using Trabecular Meshwork Analyzing Software.” American journal of ophthalmology (2025). PMID: 40324555 ↗

    L4OTHERCited in: Long-term & Definitive Management
  345. [345]

    Ho H, Daas A, Ho J et al.. “Intraocular pressure changes following topical ocular hypotensive medications washout.” The British journal of ophthalmology (2020). PMID: 32277009 ↗

    L2OTHERCited in: Long-term & Definitive Management, Prognosis & Natural History, Special Populations & Pregnancy
  346. [346]

    Rahman MQ, Abeysinghe SS, Kelly S et al.. “Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database.” The British journal of ophthalmology (2011). PMID: 21258080 ↗

    L2OTHERCited in: Long-term & Definitive Management, Special Populations & Pregnancy
  347. [347]

    Yang Y, Zhang X, Chen Z et al.. “Intraocular pressure and diurnal fluctuation of open-angle glaucoma and ocular hypertension: a baseline report from the LiGHT China trial cohort.” The British journal of ophthalmology (2022). PMID: 35086806 ↗

    L2OTHERCited in: Long-term & Definitive Management
  348. [348]

    Shabaninejad H, Homer T, Kernohan A et al.. “Is primary trabeculectomy cost-effective for patients with advanced primary open angle glaucoma? Results from the Treatment of Advanced Glaucoma Study economic model.” The British journal of ophthalmology (2024). PMID: 38336459 ↗

    L2OTHERCited in: Long-term & Definitive Management
  349. [349]

    Jóhannesson G, Lindén C, Aspberg J et al.. “Impact of mono- or multitherapy on ocular surface health and quality of life after 5 years of follow-up in the Glaucoma Intensive Treatment Study (GITS).” Acta ophthalmologica (2026). PMID: 41609297 ↗

    L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Special Populations & Pregnancy
  350. [350]

    Barkander A, Economou MA, Jóhannesson G. “Randomized Controlled Trial Comparing Cataract Surgery Alone vs. Combined with iStent Inject W or Kahook Dual Blade Glide: The Swedish Microinvasive Glaucoma Surgery Study.” Ophthalmology. Glaucoma (2025). PMID: 41461221 ↗

    L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae, Prognosis & Natural History
  351. [351]

    Nogueira PF, Vallim JRS, Barboza MNC et al.. “Effects of Melatonin Supplementation on Sleep Quality in Patients with Advanced Glaucoma: A Randomized, Double-Masked, Placebo-Controlled Crossover Trial.” Ophthalmology. Glaucoma (2025). PMID: 41386535 ↗

    L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Special Populations & Pregnancy
  352. [352]

    Sivaprasad S, Elagouz M, McHugh D et al.. “Micropulsed diode laser therapy: evolution and clinical applications.” Survey of ophthalmology (2010). PMID: 20850854 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
  353. [353]

    Tsutsui A, Hamanaka T, Kaidzu S et al.. “Comparison of Schlemm's Canal Morphology Parameters Between Propensity Score-Matched Primary Open-Angle Glaucoma and Exfoliation Glaucoma.” Investigative ophthalmology & visual science (2024). PMID: 38324302 ↗

    L3OTHERCited in: Long-term & Definitive Management
  354. [354]

    Kang JH, Wiggs JL, Rosner BA et al.. “Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with sex and postmenopausal hormone use.” Investigative ophthalmology & visual science (2009). PMID: 19815736 ↗

    L3OTHERCited in: Long-term & Definitive Management
  355. [355]

    Kawai M, Goseki T, Hirasawa K et al.. “Changes in Optic Nerve Head Blood Flow During Horizontal Ocular Duction.” Investigative ophthalmology & visual science (2024). PMID: 38170537 ↗

    L3OTHERCited in: Long-term & Definitive Management
  356. [356]

    Hardarson SH, Gottfredsdottir MS, Halldorsson GH et al.. “Glaucoma filtration surgery and retinal oxygen saturation.” Investigative ophthalmology & visual science (2009). PMID: 19494205 ↗

    L4OTHERCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  357. [357]

    Gardiner SK, Cull G, Fortune B et al.. “Increased Optic Nerve Head Capillary Blood Flow in Early Primary Open-Angle Glaucoma.” Investigative ophthalmology & visual science (2019). PMID: 31323681 ↗

    L3OTHERCited in: Long-term & Definitive Management, Prognosis & Natural History
  358. [358]

    Yousefi S, Sakai H, Murata H et al.. “Rates of Visual Field Loss in Primary Open-Angle Glaucoma and Primary Angle-Closure Glaucoma: Asymmetric Patterns.” Investigative ophthalmology & visual science (2018). PMID: 30513532 ↗

    L2OTHERCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  359. [359]

    Shin JW, Sung KR, Uhm KB et al.. “Peripapillary Microvascular Improvement and Lamina Cribrosa Depth Reduction After Trabeculectomy in Primary Open-Angle Glaucoma.” Investigative ophthalmology & visual science (2017). PMID: 29183045 ↗

    L4OTHERCited in: Long-term & Definitive Management
  360. [360]

    Kim JA, Kim TW, Lee EJ et al.. “Microvascular Changes in Peripapillary and Optic Nerve Head Tissues After Trabeculectomy in Primary Open-Angle Glaucoma.” Investigative ophthalmology & visual science (2018). PMID: 30242362 ↗

    L4OTHERCited in: Long-term & Definitive Management
  361. [361]

    Hamanaka T, Matsuda A, Sakurai T et al.. “Morphological Abnormalities of Schlemm's Canal in Primary Open-Angle Glaucoma From the Aspect of Aging.” Investigative ophthalmology & visual science (2016). PMID: 26903228 ↗

    L3OTHERCited in: Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations
  362. [362]

    Hanyuda A, Rosner BA, Wiggs JL et al.. “Low-carbohydrate-diet scores and the risk of primary open-angle glaucoma: data from three US cohorts.” Eye (London, England) (2020). PMID: 32123310 ↗

    L2OTHERCited in: Long-term & Definitive Management, Prognosis & Natural History
  363. [363]

    Bukhari SM, Kiu KY, Thambiraja R et al.. “Microvascular endothelial function and severity of primary open angle glaucoma.” Eye (London, England) (2016). PMID: 27540832 ↗

    L2OTHERCited in: Long-term & Definitive Management
  364. [364]

    Srinivasan S, Choudhari NS, Baskaran M et al.. “Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma.” Eye (London, England) (2015). PMID: 26563660 ↗

    L3OTHERCited in: Long-term & Definitive Management
  365. [365]

    Chang TC, Vanner EA, Parrish RK. “Glaucoma surgery preferences when the surgeon adopts the role of the patient.” Eye (London, England) (2019). PMID: 31043689 ↗

    L5OTHERCited in: Long-term & Definitive Management
  366. [366]

    Gottehrer J, Davey PG. “The Efficacy and Safety of Minimally Invasive Glaucoma Surgery for Primary Open-Angle Glaucoma: A Systematic Review.” Healthcare (Basel, Switzerland) (2026). PMID: 41682171 ↗

    L1SR_OBSCited in: Long-term & Definitive Management
  367. [367]

    Zhang Y, Chen Q, Lu S et al.. “Electroacupuncture as an adjunctive therapy for drug-refractory primary open-angle glaucoma: a CARE-compliant case report.” Frontiers in medicine (2026). PMID: 42338949 ↗

    L4CASE_REPORTCited in: Long-term & Definitive Management
  368. [368]

    Ko YH, Fan CC, Ko YC et al.. “Efficacy and safety of preservative-free versus preserved timolol eye drops in glaucoma: A randomized crossover study.” Journal of the Chinese Medical Association : JCMA (2026). PMID: 41501970 ↗

    L1RCTCited in: Long-term & Definitive Management
  369. [369]

    Jampel HD, Bacharach J, Sheu WP et al.. “Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure.” American journal of ophthalmology (2002). PMID: 12470755 ↗

    L1RCTCited in: History and Evolution of Treatment
  370. [370]

    Jay JL, Murray SB. “Early trabeculectomy versus conventional management in primary open angle glaucoma.” The British journal of ophthalmology (1988). PMID: 3067743 ↗

    L1RCTCited in: History and Evolution of Treatment
  371. [371]

    Evans DW, Hosking SL, Gherghel D et al.. “Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection.” The British journal of ophthalmology (2003). PMID: 14660453 ↗

    L1RCTCited in: History and Evolution of Treatment
  372. [372]

    Gazzard G, Foster PJ, Devereux JG et al.. “Intraocular pressure and visual field loss in primary angle closure and primary open angle glaucomas.” The British journal of ophthalmology (2003). PMID: 12770969 ↗

    L3RCTCited in: History and Evolution of Treatment
  373. [373]

    Hedman K, Watson PG, Alm A. “The effect of latanoprost on intraocular pressure during 2 years of treatment.” Survey of ophthalmology (2002). PMID: 12204702 ↗

    L4RCTCited in: History and Evolution of Treatment
  374. [374]

    Yamamoto T, Kitazawa Y, Azuma I et al.. “Clinical evaluation of UF-021 (Rescula; isopropyl unoprostone).” Survey of ophthalmology (1997). PMID: 9154284 ↗

    L5RCTCited in: History and Evolution of Treatment
  375. [375]

    Kaiser HJ, Flammer J, Stümpfig D et al.. “Longterm visual field follow-up of glaucoma patients treated with beta-blockers.” Survey of ophthalmology (1994). PMID: 7940137 ↗

    L2RCTCited in: History and Evolution of Treatment
  376. [376]

    DuBiner H, Cooke D, Dirks M et al.. “Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.” Survey of ophthalmology (2001). PMID: 11434938 ↗

    L1RCTCited in: History and Evolution of Treatment
  377. [377]

    Silver LH. “Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide Dose-Response Study Group.” Survey of ophthalmology (2000). PMID: 10665517 ↗

    L1RCTCited in: History and Evolution of Treatment
  378. [378]

    Silver LH. “Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group.” Survey of ophthalmology (2000). PMID: 10665516 ↗

    L1RCTCited in: History and Evolution of Treatment
  379. [379]

    Claridge KG, Smith SE. “Diurnal variation in pulsatile ocular blood flow in normal and glaucomatous eyes.” Survey of ophthalmology (1994). PMID: 7940144 ↗

    L4RCTCited in: History and Evolution of Treatment
  380. [380]

    Orzalesi N, Rossetti L, Invernizzi T et al.. “Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.” Investigative ophthalmology & visual science (2000). PMID: 10937568 ↗

    L1RCTCited in: History and Evolution of Treatment
  381. [381]

    Day AC, Machin D, Aung T et al.. “Central corneal thickness and glaucoma in East Asian people.” Investigative ophthalmology & visual science (2011). PMID: 21917940 ↗

    L3RCTCited in: History and Evolution of Treatment
  382. [382]

    Fuchsjäger-Mayrl G, Georgopoulos M, Hommer A et al.. “Effect of dorzolamide and timolol on ocular pressure: blood flow relationship in patients with primary open-angle glaucoma and ocular hypertension.” Investigative ophthalmology & visual science (2009). PMID: 19850848 ↗

    L1RCTCited in: History and Evolution of Treatment
  383. [383]

    Chiselita D. “Non-penetrating deep sclerectomy versus trabeculectomy in primary open-angle glaucoma surgery.” Eye (London, England) (2001). PMID: 11339590 ↗

    L1RCTCited in: History and Evolution of Treatment
  384. [384]

    Kang JH, Willett WC, Rosner BA et al.. “Caffeine consumption and the risk of primary open-angle glaucoma: a prospective cohort study.” Investigative ophthalmology & visual science (2008). PMID: 18263806 ↗

    L2COHORTCited in: History and Evolution of Treatment
  385. [385]

    Kang JH, Loomis SJ, Rosner BA et al.. “Comparison of Risk Factor Profiles for Primary Open-Angle Glaucoma Subtypes Defined by Pattern of Visual Field Loss: A Prospective Study.” Investigative ophthalmology & visual science (2015). PMID: 25758813 ↗

    L2COHORTCited in: History and Evolution of Treatment, Complications & Ocular Sequelae
  386. [386]

    Lichter PR. “Genetic clues to glaucoma's secrets. The L Edward Jackson Memorial Lecture. Part 2.” American journal of ophthalmology (1994). PMID: 8198155 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  387. [387]

    Chan W, Wiggs JL, Sobrin L. “The Genetic Influence on Corticosteroid-Induced Ocular Hypertension: A Field Positioned for Discovery.” American journal of ophthalmology (2019). PMID: 30763540 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  388. [388]

    Graham SL, Drance SM. “Nocturnal hypotension: role in glaucoma progression.” Survey of ophthalmology (1999). PMID: 10416743 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  389. [389]

    de Vries VA, Hanyuda A, Vergroesen JE et al.. “The Clinical Usefulness of a Glaucoma Polygenic Risk Score in 4 Population-Based European Ancestry Cohorts.” Ophthalmology (2024). PMID: 39128550 ↗

    L2OTHERCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
  390. [390]

    Smith KD, Arthurs BP, Saheb N. “An association between hypothyroidism and primary open-angle glaucoma.” Ophthalmology (1993). PMID: 8414419 ↗

    L3OTHERCited in: History and Evolution of Treatment
  391. [391]

    Mahmoudinezhad G, Nishida T, Weinreb RN et al.. “Impact of Smoking on Visual Field Progression in a Long-term Clinical Follow-up.” Ophthalmology (2022). PMID: 35752211 ↗

    L2OTHERCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
  392. [392]

    Westfall AC, Ng JD, Samples JR et al.. “Hypotonus maculopathy: magnetic resonance appearance.” American journal of ophthalmology (2004). PMID: 15013886 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  393. [393]

    Mermoud A. “Sinusotomy and deep sclerectomy.” Eye (London, England) (2000). PMID: 11026983 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  394. [394]

    Gordon MO, Gao F, Huecker JB et al.. “Evaluation of a Primary Open-Angle Glaucoma Prediction Model Using Long-term Intraocular Pressure Variability Data: A Secondary Analysis of 2 Randomized Clinical Trials.” JAMA ophthalmology (2020). PMID: 32496526 ↗

    L2OTHERCited in: History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance
  395. [395]

    Hou H, Shoji T, Zangwill LM et al.. “Progression of Primary Open-Angle Glaucoma in Diabetic and Nondiabetic Patients.” American journal of ophthalmology (2018). PMID: 29447914 ↗

    L2OTHERCited in: History and Evolution of Treatment
  396. [396]

    Mabuchi F, Mabuchi N, Sakurada Y et al.. “Genetic Variants Associated With the Onset and Progression of Primary Open-Angle Glaucoma.” American journal of ophthalmology (2020). PMID: 32217119 ↗

    L3OTHERCited in: History and Evolution of Treatment
  397. [397]

    Broadway DC, Drance SM. “Glaucoma and vasospasm.” The British journal of ophthalmology (1998). PMID: 9828767 ↗

    L4OTHERCited in: History and Evolution of Treatment
  398. [398]

    Nishida T, Mahmoudinezhad G, Weinreb RN et al.. “Smoking and progressive retinal nerve fibre layer thinning in glaucoma.” The British journal of ophthalmology (2022). PMID: 36100361 ↗

    L2OTHERCited in: History and Evolution of Treatment
  399. [399]

    Steger JS, Capó-Aponte JE, Papp A et al.. “Real-world efficacy, safety, and usability of a microvolume eyedrop delivery device in glaucoma: prospective randomized crossover trial.” Journal of cataract and refractive surgery (2026). PMID: 41185150 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications & Ocular Sequelae, Special Populations & Pregnancy
  400. [400]

    Ayub G, Costa VP. “Bent Ab Interno Needle Goniotomy Versus Gonioscopy-Assisted Transluminal Trabeculotomy in Primary Open Angle Glaucoma: A Randomized Clinical Trial.” Journal of glaucoma (2025). PMID: 40928363 ↗

    L1RCTCited in: History and Evolution of Treatment
  401. [401]

    Panarelli JF, Moster MR, Garcia-Feijoo J et al.. “Ab-Externo MicroShunt vs. Trabeculectomy in Primary Open-Angle Glaucoma: 5-Year Safety Results from a Randomized, Multicenter Study.” Ophthalmology. Glaucoma (2025). PMID: 40912402 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications & Ocular Sequelae
  402. [402]

    Lindner T, Pai V, Janku P et al.. “Single oral administration of dronabinol increases ocular blood flow in patients with glaucoma.” Acta ophthalmologica (2025). PMID: 40772417 ↗

    L1RCTCited in: History and Evolution of Treatment, Special Populations & Pregnancy
  403. [403]

    Konstas AG, Garhöfer G, Lübke J et al.. “A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.” Advances in therapy (2025). PMID: 40493333 ↗

    L1RCTCited in: History and Evolution of Treatment, Special Populations & Pregnancy, Prevention, Screening & Surveillance
  404. [404]

    Raimondi R, Sow K, Peto T et al.. “The effect of intraocular pressure during phacoemulsification in patients with either diabetic retinopathy or glaucoma; a randomized controlled feasibility trial.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2025). PMID: 40299059 ↗

    L1RCTCited in: History and Evolution of Treatment
  405. [405]

    Kass MA. “When to treat ocular hypertension.” Survey of ophthalmology (1983). PMID: 6665700 ↗

    L5OTHERCited in: History and Evolution of Treatment
  406. [406]

    Gramer G, Weber BH, Gramer E. “Migraine and Vasospasm in Glaucoma: Age-Related Evaluation of 2027 Patients With Glaucoma or Ocular Hypertension.” Investigative ophthalmology & visual science (2015). PMID: 26720447 ↗

    L4OTHERCited in: History and Evolution of Treatment
  407. [407]

    Mabuchi F, Sakurada Y, Kashiwagi K et al.. “Association between SRBD1 and ELOVL5 gene polymorphisms and primary open-angle glaucoma.” Investigative ophthalmology & visual science (2011). PMID: 21508110 ↗

    L3OTHERCited in: History and Evolution of Treatment
  408. [408]

    Villani E, Sacchi M, Magnani F et al.. “The Ocular Surface in Medically Controlled Glaucoma: An In Vivo Confocal Study.” Investigative ophthalmology & visual science (2016). PMID: 26962696 ↗

    L4OTHERCited in: History and Evolution of Treatment
  409. [409]

    Yu M, Hwang HH, Roberts AL et al.. “Childhood or adolescent abuse and primary open-angle glaucoma in a longitudinal cohort of women.” Eye (London, England) (2025). PMID: 40211014 ↗

    L2OTHERCited in: History and Evolution of Treatment
  410. [410]

    Terauchi R, Ogawa S, Sotozono A et al.. “Seasonal fluctuation in intraocular pressure and its associated factors in primary open-angle glaucoma.” Eye (London, England) (2021). PMID: 33526849 ↗

    L2OTHERCited in: History and Evolution of Treatment
  411. [411]

    Dick HB, Mackert MJ, Ahmed IIK et al.. “Two-Year Performance and Safety Results of the MINIject Supraciliary Implant in Patients With Primary Open-Angle Glaucoma: Meta-Analysis of the STAR-I, II, III Trials.” American journal of ophthalmology (2023). PMID: 38109951 ↗

    L2SR_OBSCited in: Surgical, Laser & Procedural Considerations, Special Populations & Pregnancy
  412. [412]

    Berdahl JP, Fautsch MP, Stinnett SS et al.. “Intracranial pressure in primary open angle glaucoma, normal tension glaucoma, and ocular hypertension: a case-control study.” Investigative ophthalmology & visual science (2008). PMID: 18719086 ↗

    L3CASE_CONTROLCited in: Surgical, Laser & Procedural Considerations
  413. [413]

    Stewart WC, Stewart JA, Nasser QJ et al.. “Cost-effectiveness of treating ocular hypertension.” Ophthalmology (2008). PMID: 18166406 ↗

    L5OTHERCited in: Surgical, Laser & Procedural Considerations
  414. [414]

    Holekamp NM. “The vitreous gel: more than meets the eye.” American journal of ophthalmology (2009). PMID: 19875090 ↗

    L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
  415. [415]

    Skuta GL, Ding K, Lum F et al.. “An IRIS Registry-Based Assessment of Primary Open-Angle Glaucoma Practice Patterns in Academic Versus Nonacademic Settings.” American journal of ophthalmology (2022). PMID: 35469787 ↗

    L2OTHERCited in: Surgical, Laser & Procedural Considerations
  416. [416]

    Fu DJ, Ademisoye E, Shih V et al.. “Survival of medical treatment success in primary open-angle glaucoma and ocular hypertension.” The British journal of ophthalmology (2024). PMID: 38664004 ↗

    L2OTHERCited in: Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance
  417. [417]

    Huang Z, Chen C, Meng J et al.. “Associations Among Sleep Duration, Sleep Quality, and Age-Related Ocular Diseases: Insights From Longitudinal and Mediation Analyses.” Investigative ophthalmology & visual science (2025). PMID: 40767441 ↗

    L2OTHERCited in: Surgical, Laser & Procedural Considerations
  418. [418]

    Park HY, Yi R, Jung Y et al.. “Effect of Glaucoma Surgery on the Progression Rate and Pattern in Glaucoma Patients With Myopia.” Investigative ophthalmology & visual science (2016). PMID: 27537267 ↗

    L2OTHERCited in: Surgical, Laser & Procedural Considerations
  419. [419]

    Sakimoto S, Okazaki T, Usui S et al.. “Cross-Sectional Imaging Analysis of Epiretinal Membrane Involvement in Unilateral Open-Angle Glaucoma Severity.” Investigative ophthalmology & visual science (2018). PMID: 30516818 ↗

    L4OTHERCited in: Surgical, Laser & Procedural Considerations
  420. [420]

    Sharma S, Bollinger KE, Kodeboyina SK et al.. “Proteomic Alterations in Aqueous Humor From Patients With Primary Open Angle Glaucoma.” Investigative ophthalmology & visual science (2018). PMID: 29847670 ↗

    L3OTHERCited in: Surgical, Laser & Procedural Considerations
  421. [421]

    Wan Y, Cao K, Wang J et al.. “Gonioscopy-assisted Transluminal Trabeculotomy (GATT) combined phacoemulsification surgery: Outcomes at a 2-year follow-up.” Eye (London, England) (2022). PMID: 35610359 ↗

    L4OTHERCited in: Surgical, Laser & Procedural Considerations
  422. [422]

    Wang Y, Wang H, Han Y et al.. “Outcomes of gonioscopy-assisted transluminal trabeculotomy in juvenile-onset primary open-angle glaucoma.” Eye (London, England) (2020). PMID: 33262477 ↗

    L4OTHERCited in: Surgical, Laser & Procedural Considerations
  423. [423]

    Chen T, Tian Y, Zhu Y et al.. “Postoperative Risk and Climate Exposure: A Retrospective Study of Incisional Glaucoma Surgery Outcomes.” Translational vision science & technology (2026). PMID: 42041186 ↗

    L2COHORTCited in: Surgical, Laser & Procedural Considerations
  424. [424]

    Liu J, Zuo M, Liu X. “Efficacy and safety of netarsudil compared with prostaglandin-based therapies: a Bayesian network meta-analysis.” International ophthalmology (2026). PMID: 42133103 ↗

    L1SR_OBSCited in: Surgical, Laser & Procedural Considerations
  425. [425]

    Abboud I, Khudari AZ, Abdelaal A et al.. “Systemic α₂-agonist use and lower hazard of glaucoma compared with β-blockers: a cohort study.” BMJ open ophthalmology (2026). PMID: 42097844 ↗

    L2COHORTCited in: Surgical, Laser & Procedural Considerations
  426. [426]

    Aung T, Laganovska G, Hernandez Paredes TJ et al.. “Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.” Ophthalmology (2014). PMID: 25064721 ↗

    L1RCTCited in: Complications & Ocular Sequelae, Special Populations & Pregnancy
  427. [427]

    Samuelson TW, Chang DF, Marquis R et al.. “A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study.” Ophthalmology (2018). PMID: 29945799 ↗

    L1RCTCited in: Complications & Ocular Sequelae
  428. [428]

    Ahmed IIK, Rhee DJ, Jones J et al.. “Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract.” Ophthalmology (2020). PMID: 33166551 ↗

    L1RCTCited in: Complications & Ocular Sequelae, Prognosis & Natural History
  429. [429]

    Konstas AG, Mikropoulos D, Kaltsos K et al.. “24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma.” Ophthalmology (2006). PMID: 16513458 ↗

    L1RCTCited in: Complications & Ocular Sequelae
  430. [430]

    Yamamoto T, Ikegami T, Ishikawa Y et al.. “Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension.” American journal of ophthalmology (2016). PMID: 27565224 ↗

    L1RCTCited in: Complications & Ocular Sequelae
  431. [431]

    Realini T, Shillingford-Ricketts H, Burt D et al.. “West Indies Glaucoma Laser Study (WIGLS): 1. 12-Month Efficacy of Selective Laser Trabeculoplasty in Afro-Caribbeans With Glaucoma.” American journal of ophthalmology (2017). PMID: 28962966 ↗

    L1RCTCited in: Complications & Ocular Sequelae
  432. [432]

    Berlin MS, Rowe-Rendleman C, Ahmed I et al.. “EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study.” The British journal of ophthalmology (2015). PMID: 26453641 ↗

    L1RCTCited in: Complications & Ocular Sequelae
  433. [433]

    Konstas AG, Mikropoulos D, Haidich AB et al.. “Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma.” The British journal of ophthalmology (2008). PMID: 19019932 ↗

    L1RCTCited in: Complications & Ocular Sequelae
  434. [434]

    Konstas AG, Quaranta L, Katsanos A et al.. “Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.” The British journal of ophthalmology (2013). PMID: 23681371 ↗

    L2RCTCited in: Complications & Ocular Sequelae
  435. [435]

    Denis P, Aptel F, Rouland JF et al.. “Cyclocoagulation of the ciliary bodies by high-intensity focused ultrasound: a 12-month multicenter study.” Investigative ophthalmology & visual science (2015). PMID: 25604688 ↗

    L2RCTCited in: Complications & Ocular Sequelae
  436. [436]

    Inoue K, Shiokawa M, Katakura S et al.. “Periocular Adverse Reactions to Omidenepag Isopropyl.” American journal of ophthalmology (2021). PMID: 34942112 ↗

    L2TRIAL_NONRANDOMCited in: Complications & Ocular Sequelae
  437. [437]

    Miglior S, Grunden JW, Kwok K. “Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension.” Eye (London, England) (2009). PMID: 20019759 ↗

    L1RCTCited in: Complications & Ocular Sequelae, Special Populations & Pregnancy, Prevention, Screening & Surveillance
  438. [438]

    Konstas AG, Katsimpris IE, Kaltsos K et al.. “Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components.” Eye (London, England) (2007). PMID: 17571086 ↗

    L1RCTCited in: Complications & Ocular Sequelae
  439. [439]

    Han X, Hewitt AW, MacGregor S. “Predicting the Future of Genetic Risk Profiling of Glaucoma: A Narrative Review.” JAMA ophthalmology (2021). PMID: 33331888 ↗

    L5REVIEW_NARRATIVECited in: Complications & Ocular Sequelae
  440. [440]

    Wang SY, Singh K, Stein JD et al.. “Ocular Antihypertensive Medication Use After iStent Implantation Concurrent With Cataract Surgery vs Cataract Surgery Alone in a Large US Health Care Claims Database.” JAMA ophthalmology (2019). PMID: 30267072 ↗

    L2OTHERCited in: Complications & Ocular Sequelae
  441. [441]

    Gabbay IE, Allen F, Morley C et al.. “Efficacy and safety data for the XEN45 implant at 2 years: a retrospective analysis.” The British journal of ophthalmology (2019). PMID: 31727624 ↗

    L4OTHERCited in: Complications & Ocular Sequelae
  442. [442]

    Desai P, Minassian DC, Reidy A et al.. “Number of incident cases of the main eye diseases of ageing in the UK Biobank cohort, projected over a 25-year period from time of recruitment.” The British journal of ophthalmology (2018). PMID: 29437582 ↗

    L2OTHERCited in: Complications & Ocular Sequelae
  443. [443]

    Liuska PJ, Rämö JT, Lemmelä S et al.. “Association of APOE Haplotypes With Common Age-Related Ocular Diseases in 412,171 Individuals.” Investigative ophthalmology & visual science (2023). PMID: 37988105 ↗

    L2OTHERCited in: Complications & Ocular Sequelae
  444. [444]

    Ohira S, Inoue T, Shobayashi K et al.. “Simultaneous increase in multiple proinflammatory cytokines in the aqueous humor in neovascular glaucoma with and without intravitreal bevacizumab injection.” Investigative ophthalmology & visual science (2015). PMID: 26030108 ↗

    L3OTHERCited in: Complications & Ocular Sequelae
  445. [445]

    Ashaye A, Ashaolu O, Komolafe O et al.. “Prevalence and types of glaucoma among an indigenous African population in southwestern Nigeria.” Investigative ophthalmology & visual science (2013). PMID: 24135752 ↗

    L4OTHERCited in: Complications & Ocular Sequelae
  446. [446]

    Datta S, Baudouin C, Brignole-Baudouin F et al.. “The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells.” Investigative ophthalmology & visual science (2017). PMID: 28444329 ↗

    L5OTHERCited in: Complications & Ocular Sequelae
  447. [447]

    Bae HW, Lee EJ, Jung JJ et al.. “Effectiveness and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution in Treatment-Naive Patients With Primary Open Angle Glaucoma: A Prospective Multicenter Phase IV Study.” Journal of glaucoma (2025). PMID: 40838859 ↗

    L4TRIAL_NONRANDOMCited in: Complications & Ocular Sequelae
  448. [448]

    Bao J, Yu Y, Chen G et al.. “Effect of antioxidants on primary open-angle glaucoma: a systematic review and meta-analysis.” Frontiers in pharmacology (2025). PMID: 40978491 ↗

    L1SR_OBSCited in: Complications & Ocular Sequelae
  449. [449]

    Theilig T, Papadimitriou M, Meller D et al.. “PRESERFLO™ MicroShunt as a treatment option for highly increased intraocular pressure in primary open angle glaucoma and pseudoexfoliation glaucoma.” Eye (London, England) (2025). PMID: 40389561 ↗

    L4OTHERCited in: Complications & Ocular Sequelae
  450. [450]

    Katsimpris A, Baumeister SE, Voulgari N et al.. “Intraocular pressure, primary open-angle glaucoma and the risk of retinal vein occlusion: A Mendelian randomization mediation analysis.” Eye (London, England) (2024). PMID: 39147865 ↗

    L2OTHERCited in: Complications & Ocular Sequelae
  451. [451]

    Levine RA, Demirel S, Fan J et al.. “Asymmetries and visual field summaries as predictors of glaucoma in the ocular hypertension treatment study.” Investigative ophthalmology & visual science (2006). PMID: 16936102 ↗

    L2RCTCited in: Prognosis & Natural History
  452. [452]

    Zhang Y, Yu P, Zhang Y et al.. “Influence of Goniotomy Size on Treatment Safety and Efficacy for Primary Open-Angle Glaucoma: A Multicenter Study.” American journal of ophthalmology (2023). PMID: 37573988 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis & Natural History, Special Populations & Pregnancy
  453. [453]

    Salazar D, Morales E, Rabiolo A et al.. “Pointwise Methods to Measure Long-term Visual Field Progression in Glaucoma.” JAMA ophthalmology (2020). PMID: 32239185 ↗

    L2OTHERCited in: Prognosis & Natural History
  454. [454]

    Mansouri K, Gillmann K, Rao HL et al.. “Measurement of intraocular temperature in glaucoma: week-day and seasonal fluctuations.” The British journal of ophthalmology (2022). PMID: 35443998 ↗

    L2OTHERCited in: Prognosis & Natural History
  455. [455]

    Stamer WD, Perkumas KM, Kang MH et al.. “Proposed Mechanism of Long-Term Intraocular Pressure Lowering With the Bimatoprost Implant.” Investigative ophthalmology & visual science (2023). PMID: 36877514 ↗

    L5OTHERCited in: Prognosis & Natural History, Special Populations & Pregnancy
  456. [456]

    Bak E, Kim YK, Ha A et al.. “Association of Intereye Visual-Sensitivity Asymmetry With Progression of Primary Open-Angle Glaucoma.” Investigative ophthalmology & visual science (2021). PMID: 34228087 ↗

    L2OTHERCited in: Prognosis & Natural History
  457. [457]

    King AJ, Rotchford AP. “Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication.” JAMA ophthalmology (2016). PMID: 27148831 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  458. [458]

    Sugali CK, Rayana NP, Dai J et al.. “GSK3β Inhibitors Inhibit TGFβ Signaling in the Human Trabecular Meshwork.” Investigative ophthalmology & visual science (2024). PMID: 39087933 ↗

    L5OTHERCited in: Special Populations & Pregnancy
  459. [459]

    Fan X, Xu H, Zhai R et al.. “Retinal Microcirculatory Responses to Hyperoxia in Primary Open-Angle Glaucoma Using Optical Coherence Tomography Angiography.” Investigative ophthalmology & visual science (2021). PMID: 34730793 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  460. [460]

    Fan BJ, Bailey JC, Igo RP et al.. “Association of a Primary Open-Angle Glaucoma Genetic Risk Score With Earlier Age at Diagnosis.” JAMA ophthalmology (2019). PMID: 31436842 ↗

    L3OTHERCited in: Prevention, Screening & Surveillance
  461. [461]

    He X, Huang Y, Plotnikov D et al.. “Nonuniform Association of Genetic Risk Scores for Intraocular Pressure.” JAMA ophthalmology (2026). PMID: 42060295 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  462. [462]

    Masis M, Chen R, Porco T et al.. “Trabecular Meshwork Height in Primary Open-Angle Glaucoma Versus Primary Angle-Closure Glaucoma.” American journal of ophthalmology (2017). PMID: 28887118 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  463. [463]

    Yoo K, Wu L, James A et al.. “Risk-Stratified Monitoring of Open Angle Glaucoma Suspects Based on Diagnostic Conversion Risk.” American journal of ophthalmology (2026). PMID: 42242412 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  464. [464]

    Ramirez M, Zheng Y, Tseng VL et al.. “Strabismus Increases Glaucoma Risk in California Medicare Beneficiaries.” American journal of ophthalmology (2025). PMID: 41419076 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  465. [465]

    Vajaranant TS, Wu S, Torres M et al.. “The changing face of primary open-angle glaucoma in the United States: demographic and geographic changes from 2011 to 2050.” American journal of ophthalmology (2012). PMID: 22541661 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  466. [466]

    Sterling J, Hua P, Dunaief JL et al.. “Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma.” The British journal of ophthalmology (2021). PMID: 34413054 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  467. [467]

    Alawa KA, Nolan RP, Han E et al.. “Low-cost, smartphone-based frequency doubling technology visual field testing using a head-mounted display.” The British journal of ophthalmology (2019). PMID: 31530566 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  468. [468]

    Rahman MQ, Montgomery DM, Lazaridou MN. “Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years' experience.” The British journal of ophthalmology (2009). PMID: 19628493 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  469. [469]

    Sung VC, Koppens JM, Vernon SA et al.. “Longitudinal glaucoma screening for siblings of patients with primary open angle glaucoma: the Nottingham Family Glaucoma Screening Study.” The British journal of ophthalmology (2006). PMID: 16361669 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  470. [470]

    Shaikh A, Salmon JF. “The role of scanning laser polarimetry using the GDx variable corneal compensator in the management of glaucoma suspects.” The British journal of ophthalmology (2006). PMID: 16885189 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  471. [471]

    Goldberg DF, Orlich C, Flowers BE et al.. “A Randomized Controlled Trial Comparing STREAMLINE Canaloplasty to Trabecular Micro-Bypass Stent Implantation in Primary Open-Angle Glaucoma.” Clinical ophthalmology (Auckland, N.Z.) (2024). PMID: 39429442 ↗

    L1RCTCited in: Prevention, Screening & Surveillance
  472. [472]

    Jiang C, Melles RB, Sangani P et al.. “Association of Behavioral and Clinical Risk Factors With Cataract: A Two-Sample Mendelian Randomization Study.” Investigative ophthalmology & visual science (2023). PMID: 37459064 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  473. [473]

    Zhou X, Li Z, Zhang X et al.. “Digoxin Attenuates Ocular Hypertension and Protects Trabecular Meshwork Cells via Ferroptosis Inhibition.” Investigative ophthalmology & visual science (2026). PMID: 41563015 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  474. [474]

    Liu Y, Wang Y, Chen Y et al.. “Discovery and Validation of Circulating Hsa-miR-210-3p as a Potential Biomarker for Primary Open-Angle Glaucoma.” Investigative ophthalmology & visual science (2019). PMID: 31284309 ↗

    L3OTHERCited in: Prevention, Screening & Surveillance
  475. [475]

    Xiao X, Huang C, Cao Y et al.. “Exome Sequencing Reveals a Heterozygous OAS3 Mutation in a Chinese Family With Juvenile-Onset Open-Angle Glaucoma.” Investigative ophthalmology & visual science (2019). PMID: 31618764 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  476. [476]

    Gharahkhani P, Burdon KP, Hewitt AW et al.. “Accurate Imputation-Based Screening of Gln368Ter Myocilin Variant in Primary Open-Angle Glaucoma.” Investigative ophthalmology & visual science (2015). PMID: 26237198 ↗

    L3OTHERCited in: Prevention, Screening & Surveillance
  477. [477]

    Shan S, Zhou J, Wu J et al.. “National, regional, and provincial prevalence of glaucoma in China in 2020: an updated systematic review and modelling analysis.” Journal of global health (2025). PMID: 41070432 ↗

    L2SR_OBSCited in: Prevention, Screening & Surveillance
  478. [478]

    Li F, Luo Y, Li X et al.. “Association between metabolic syndrome and the risk of glaucoma: a meta-analysis of observational studies.” Diabetology & metabolic syndrome (2024). PMID: 39696489 ↗

    L3SR_OBSCited in: Prevention, Screening & Surveillance
  479. [479]

    Liu Q, Davis J, Han X et al.. “Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia.” Eye (London, England) (2022). PMID: 36513856 ↗

    L5OTHERCited in: Prevention, Screening & Surveillance
  480. [480]

    Gupta V, Somarajan BI, Gupta S et al.. “The mutational spectrum of Myocilin gene among familial versus sporadic cases of Juvenile onset open angle glaucoma.” Eye (London, England) (2020). PMID: 32300215 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance

Revision History

All updates applied to this page

Loading revisions…